The giving of drugs, chemicals, or other substances by mouth.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Injections made into a vein for therapeutic or experimental purposes.
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
The various ways of administering a drug or other chemical to a site in a patient or animal from where the chemical is absorbed into the blood and delivered to the target tissue.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
Elements of limited time intervals, contributing to particular results or situations.
Delivery of medications through the nasal mucosa.
A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.
Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
The insertion of drugs into the rectum, usually for confused or incompetent patients, like children, infants, and the very old or comatose.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.
Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.
The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.
Delivery of substances through VENIPUNCTURE into the VEINS.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992)
Injections into the cerebral ventricles.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding.
The application of suitable drug dosage forms to the skin for either local or systemic effects.
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed)
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Administration of a soluble dosage form by placement under the tongue.
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.
The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping.
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects.
The observable response an animal makes to any situation.
Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL.
The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle.
Proteins prepared by recombinant DNA technology.
Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard.
Introduction of substances into the body using a needle and syringe.
A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable.
Introduction of therapeutic agents into the spinal region using a needle and syringe.
The measurement of an organ in volume, mass, or heaviness.
Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site.
Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS.
Administration of a drug or chemical by the individual under the direction of a physician. It includes administration clinically or experimentally, by human or animal.
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES.
The number of times the HEART VENTRICLES contract per unit of time, usually per minute.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.
The physical activity of a human or an animal as a behavioral phenomenon.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
Compounds capable of relieving pain without the loss of CONSCIOUSNESS.
Therapy with two or more separate preparations given for a combined effect.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Delivery of drugs into an artery.
Administration of a soluble dosage form between the cheek and gingiva. It may involve direct application of a drug onto the buccal mucosa, as by painting or spraying.
An encapsulated lymphatic organ through which venous blood filters.
A family of hexahydropyridines.
A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
Antibodies produced by a single clone of cells.
Uptake of substances through the lining of the INTESTINES.
Glucose in blood.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
The action of a drug in promoting or enhancing the effectiveness of another drug.
An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.
A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.
The consumption of edible substances.
One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.
Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.
A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP.
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.
The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed)
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Dosage forms of a drug that act over a period of time by controlled-release processes or technology.
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).
Scales, questionnaires, tests, and other methods used to assess pain severity and duration in patients or experimental animals to aid in diagnosis, therapy, and physiological studies.
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.
Substances that reduce or suppress INFLAMMATION.
Substances that reduce the growth or reproduction of BACTERIA.
A technique for measuring extracellular concentrations of substances in tissues, usually in vivo, by means of a small probe equipped with a semipermeable membrane. Substances may also be introduced into the extracellular space through the membrane.
An anti-inflammatory 9-fluoro-glucocorticoid.
The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized.
The insertion of drugs into the vagina to treat local infections, neoplasms, or to induce labor. The dosage forms may include medicated pessaries, irrigation fluids, and suppositories.
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
Refers to animals in the period of time just after birth.
Naturally occurring or synthetic substances that inhibit or retard the oxidation of a substance to which it is added. They counteract the harmful and damaging effects of oxidation in animal tissues.
The measure of the level of heat of a human or animal.
Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
Agents inhibiting the effect of narcotics on the central nervous system.
The rate dynamics in chemical or physical systems.
An emulsifying agent produced in the LIVER and secreted into the DUODENUM. Its composition includes BILE ACIDS AND SALTS; CHOLESTEROL; and ELECTROLYTES. It aids DIGESTION of fats in the duodenum.
A cabinet department in the Executive Branch of the United States Government concerned with overall planning, promoting, and administering programs pertaining to VETERANS. It was established March 15, 1989 as a Cabinet-level position.
A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.
Use of plants or herbs to treat diseases or to alleviate pain.
Chinese herbal or plant extracts which are used as drugs to treat diseases or promote general well-being. The concept does not include synthesized compounds manufactured in China.
Drugs used to cause dilation of the blood vessels.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity.
Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Process that is gone through in order for a device to receive approval by a government regulatory agency. This includes any required preclinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance. It is not restricted to FDA.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Fluid propulsion systems driven mechanically, electrically, or osmotically that are used to inject (or infuse) over time agents into a patient or experimental animal; used routinely in hospitals to maintain a patent intravenous line, to administer antineoplastic agents and other drugs in thromboembolism, heart disease, diabetes mellitus (INSULIN INFUSION SYSTEMS is also available), and other disorders.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.
The flow of BLOOD through or around an organ or region of the body.
A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.
A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator.
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.
An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.
Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.
An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP).
Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.
The surgical removal of one or both ovaries.
An increased sensation of pain or discomfort produced by mimimally noxious stimuli due to damage to soft tissue containing NOCICEPTORS or injury to a peripheral nerve.
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS.
The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE.
A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.
A non-steroidal anti-inflammatory agent (NSAID) that inhibits the enzyme cyclooxygenase necessary for the formation of prostaglandins and other autacoids. It also inhibits the motility of polymorphonuclear leukocytes.
Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states.
Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol.
Medicated dosage forms that are designed to be inserted into the rectal, vaginal, or urethral orifice of the body for absorption. Generally, the active ingredients are packaged in dosage forms containing fatty bases such as cocoa butter, hydrogenated oil, or glycerogelatin that are solid at room temperature but melt or dissolve at body temperature.
Ventral part of the DIENCEPHALON extending from the region of the OPTIC CHIASM to the caudal border of the MAMMILLARY BODIES and forming the inferior and lateral walls of the THIRD VENTRICLE.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM.
An NADPH-dependent enzyme that catalyzes the conversion of L-ARGININE and OXYGEN to produce CITRULLINE and NITRIC OXIDE.
Implanted fluid propulsion systems with self-contained power source for providing long-term controlled-rate delivery of drugs such as chemotherapeutic agents or analgesics. Delivery rate may be externally controlled or osmotically or peristatically controlled with the aid of transcutaneous monitoring.
A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN).
Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS.
A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi).
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
Disease having a short and relatively severe course.
Substances which lower blood glucose levels.
Toxins closely associated with the living cytoplasm or cell wall of certain microorganisms, which do not readily diffuse into the culture medium, but are released upon lysis of the cells.
Any of the ruminant mammals with curved horns in the genus Ovis, family Bovidae. They possess lachrymal grooves and interdigital glands, which are absent in GOATS.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.
Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke.
A group of compounds that contain the structure SO2NH2.
A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer.
Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE.
Lining of the INTESTINES, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. In the SMALL INTESTINE, the mucosa is characterized by a series of folds and abundance of absorptive cells (ENTEROCYTES) with MICROVILLI.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.

Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. (1/1580)

Transcutaneous immunization (TCI) is a new technique that uses the application of vaccine antigens in a solution on the skin to induce potent antibody responses without systemic or local toxicity. We have previously shown that cholera toxin (CT), a potent adjuvant for oral and nasal immunization, can induce both serum and mucosal immunoglobulin G (IgG) and IgA and protect against toxin-mediated mucosal disease when administered by the transcutaneous route. Additionally, CT acts as an adjuvant for coadministered antigens such as tetanus and diphtheria toxoids when applied to the skin. CT, a member of the bacterial ADP-ribosylating exotoxin (bARE) family, is most potent as an adjuvant when the A-B subunits are present and functional. We now show that TCI induces secondary antibody responses to coadministered antigens as well as to CT in response to boosting immunizations. IgG antibodies to coadministered antigens were also found in the stools and lung washes of immunized mice, suggesting that TCI may target mucosal pathogens. Mice immunized by the transcutaneous route with tetanus fragment C and CT developed anti-tetanus toxoid antibodies and were protected against systemic tetanus toxin challenge. We also show that bAREs, similarly organized as A-B subunits, as well as the B subunit of CT alone, induced antibody responses to themselves when given via TCI. Thus, TCI appears to induce potent, protective immune responses to both systemic and mucosal challenge and offers significant potential practical advantages for vaccine delivery.  (+info)

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. (2/1580)

BACKGROUND AND METHODS: Use of nicotine-replacement therapies and the antidepressant bupropion helps people stop smoking. We conducted a double-blind, placebo-controlled comparison of sustained-release bupropion (244 subjects), a nicotine patch (244 subjects), bupropion and a nicotine patch (245 subjects), and placebo (160 subjects) for smoking cessation. Smokers with clinical depression were excluded. Treatment consisted of nine weeks of bupropion (150 mg a day for the first three days, and then 150 mg twice daily) or placebo, as well as eight weeks of nicotine-patch therapy (21 mg per day during weeks 2 through 7, 14 mg per day during week 8, and 7 mg per day during week 9) or placebo. The target day for quitting smoking was usually day 8. RESULTS: The abstinence rates at 12 months were 15.6 percent in the placebo group, as compared with 16.4 percent in the nicotine-patch group, 30.3 percent in the bupropion group (P<0.001), and 35.5 percent in the group given bupropion and the nicotine patch (P<0.001). By week 7, subjects in the placebo group had gained an average of 2.1 kg, as compared with a gain of 1.6 kg in the nicotine-patch group, a gain of 1.7 kg in the bupropion group, and a gain of 1.1 kg in the combined-treatment group (P<0.05). Weight gain at seven weeks was significantly less in the combined-treatment group than in the bupropion group and the placebo group (P<0.05 for both comparisons). A total of 311 subjects (34.8 percent) discontinued one or both medications. Seventy-nine subjects stopped treatment because of adverse events: 6 in the placebo group (3.8 percent), 16 in the nicotine-patch group (6.6 percent), 29 in the bupropion group (11.9 percent), and 28 in the combined-treatment group (11.4 percent). The most common adverse events were insomnia and headache. CONCLUSIONS: Treatment with sustained-release bupropion alone or in combination with a nicotine patch resulted in significantly higher long-term rates of smoking cessation than use of either the nicotine patch alone or placebo. Abstinence rates were higher with combination therapy than with bupropion alone, but the difference was not statistically significant.  (+info)

Extraction and analysis of cosmetic active ingredients from an anti-cellulitis transdermal delivery system by high-performance liquid chromatography. (3/1580)

A new transdermal delivery system that controls cellulitis is evaluated using reversed-phase high-performance liquid chromatography coupled with photodiode array detection. An extraction procedure and the validation of the analytical method to assay the active excipients from the Centella asiatica plant (asiaticoside, madacessic acid, and asiatic acid) are described. Excellent results ae obtained in terms of linearity, accuracy, and specificity of the analytical method.  (+info)

Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. (4/1580)

The Collaborative European Anti-Smoking Evaluation (CEASE) was a European multicentre, randomized, double-blind placebo controlled smoking cessation study. The objectives were to determine whether higher dosage and longer duration of nicotine patch therapy would increase the success rate. Thirty-six chest clinics enrolled a total of 3,575 smokers. Subjects were allocated to one of five treatment arms: placebo and either standard or higher dose nicotine patches (15 mg and 25 mg daily) each given for 8 or 22 weeks with adjunctive moderately intensive support. The 12 month sustained success rates were: 25 mg patch for 22 weeks (L-25), 15.4%; 25 mg patch for 8 weeks (S-25), 15.9%; 15 mg patch for 22 weeks (L-15), 13.7%; 15 mg patch for 8 weeks (S-15), 11.7%; and placebo (P-0) 9.9% (placebo versus 15 mg, p<0.05; 25 mg versus 15 mg, p<0.03; 25 mg versus placebo, p<0.001, Chi-squared test). There was no significant difference in success rate between the two active treatment durations. Of the first week abstainers (n=1,698), 25.1% achieved success at 12 months as opposed to first week smokers, 2.7% of 1,877 subjects (p< 0.001). In summary, a higher than standard dose of nicotine patch was associated with an increase in the long-term success in smoking cessation but continuation of treatment beyond 8-12 weeks did not increase the success rates.  (+info)

Topical psoriasis therapy. (5/1580)

Psoriasis is a common dermatosis, affecting from 1 to 3 percent of the population. Until recently, the mainstays of topical therapy have been corticosteroids, tars, anthralins and keratolytics. Recently, however, vitamin D analogs, a new anthralin preparation and topical retinoids have expanded physicians' therapeutic armamentarium. These new topical therapies offer increased hope and convenience to the large patient population with psoriasis.  (+info)

A successful tobacco cessation program led by primary care nurses in a managed care setting. (6/1580)

We conducted a descriptive study of a tobacco cessation program sponsored by a health maintenance organization (HMO) and led by primary care nurses. The tobacco cessation program was conducted at 20 primary care clinics in northeastern and central Pennsylvania. We gauged the successfulness of the program by the patients' self-reported quit rates at 1 year. We also examined the association between quit rates and compliance with scheduled counseling visits, the impact of the availability of an HMO pharmacy benefit that supported the costs of nicotine replacement therapy, and the quit rates among patients with HMO insurance versus those with insurance other than managed care. Of 1,695 patients enrolled in the program from July 1993 to March 1996, 1,140 completed 1 year of follow-up. Of these, 348 (30.5%) reported they had quit using tobacco. Among the 810 HMO enrollees who participated in the program, the quit rate was 280 (34.6%); among the 330 non-HMO participants, the quit rate was 69 (20.9%), a statistically significant difference (P < 0.001). For all patients, keeping more than four visits with the program nurse was associated with a significantly higher likelihood of quitting (317/751 [42.2%] versus 32/389 [8.2%]; P < 0.001). Non-HMO patients were less likely than HMO enrollees to keep four or more visits (165 [50%] versus 586 [72.3%]; P < 0.001). We were unable to detect a difference in quit rates among those with and those without a pharmacy benefit (196/577 [34%] versus 84/233 [36.1%]). These data are limited by their descriptive nature and the lack of information about other factors important in determining the quit rate among program participants. Nevertheless, they suggest that HMOs can successfully sponsor nurse-led tobacco cessation programs in multiple primary care settings and achieve 1-year quit rates significantly higher than the 15% quit rate reported in the medical literature. In addition, successfully quitting tobacco use appeared to be associated with use of counseling visits but not with use of a pharmacy benefit to pay for nicotine replacement therapy. Even though tobacco cessation programs have the best chance of benefitting HMO enrollees, patients not enrolled in managed care plans also appear to benefit significantly. This finding has important implications for developing future strategies--including the role of managed care organizations, the need to defray the costs of nicotine replacement therapy, and the best approach to provide counseling to patients--to meet the Healthy People 2000 goal of reducing tobacco smoking.  (+info)

The effects of vapreotide, a somatostatin analogue, on gastric acidity, gallbladder emptying and hormone release after 1 week of continuous subcutaneous infusion in normal subjects. (7/1580)

AIMS: Somatostatin analogues (e.g. vapreotide) are used for treatment of acromegaly, endocrine tumours and variceal bleeding. The pharmacodynamic effects of vapreotide have, however, not been documented in the gastrointestinal tract. The aim of this study was to investigate the effects of continuous vapreotide administration on gastric acidity, gallbladder contraction and hormone release. METHODS: Ten healthy males participated in this randomised, placebo-controlled, double-blind, crossover trial. A constant vapreotide (or placebo) infusion (1.5 mg day(-1) s.c.) was given for 7 days with a portable pump. Intragastric pH was monitored on days 2 and 7. Gallbladder volume was sonographically assessed and the maximal ejection fraction was calculated. In addition basal and postprandial plasma levels of gastrin and cholecystokinin (CCK) were measured. RESULTS: After an initial increase in the median 24 h intragastric pH to a value of 2.6 on day 2, vapreotide's effect on pH decreased: (day 7: median pH=1.9; respective placebo values were 1.7 and 1.5). On the same days with vapreotide treatment, gallbladder contraction and plasma levels of CCK were reduced; maximal ejection fractions after meal stimulation were 18% and 20% (respective placebo values were 57% and 62%). Plasma gastrin levels were not changed with vapreotide treatment. CONCLUSIONS: The short lasting effect of vapreotide on intragastric acidity suggests a down-regulation of somatostatin receptors during treatment. The lack of effect on gastrin indicates that the effects on gastric pH are not mediated by gastrin. Constant vapreotide infusion (but not placebo) reduced gallbladder contraction suggesting a long-lasting effect on biliary function.  (+info)

Low dose subcutaneous adrenaline to prevent acute adverse reactions to antivenom serum in people bitten by snakes: randomised, placebo controlled trial. (8/1580)

OBJECTIVE: To assess the efficacy and safety of low dose adrenaline injected subcutaneously to prevent acute adverse reactions to polyspecific antivenom serum in patients admitted to hospital after snake bite. DESIGN: Prospective, double blind, randomised, placebo controlled trial. SETTING: District general hospital in Sri Lanka. SUBJECTS: 105 patients with signs of envenomation after snake bite, randomised to receive either adrenaline (cases) or placebo (controls) immediately before infusion of antivenom serum. INTERVENTIONS: Adrenaline 0.25 ml (1:1000). MAIN OUTCOME MEASURES: Development of acute adverse reactions to serum and side effects attributable to adrenaline. RESULTS: 56 patients (cases) received adrenaline and 49 (controls) received placebo as pretreatment. Six (11%) adrenaline patients and 21 (43%) control patients developed acute adverse reactions to antivenom serum (P=0.0002). Significant reductions in acute adverse reactions to serum were also seen in the adrenaline patients for each category of mild, moderate, and severe reactions. There were no significant adverse effects attributable to adrenaline. CONCLUSIONS: Use of 0.25 ml of 1:1000 adrenaline given subcutaneously immediately before administration of antivenom serum to patients with envenomation after snake bite reduces the incidence of acute adverse reactions to serum.  (+info)

Futuristic Reports, gives excellent assurance of the report, integrated from various professional and trusted sources. Global Transdermal Drug Delivery System market report 2020, offers significant knowledge about market players, segments, revenue, profit, restrain, share, size, etc. Transdermal Drug Delivery System Report analysis is done on the basis of quality content assurance and from highly educated and experienced analyst. While providing and collecting Transdermal Drug Delivery System information for the report, many of the circumstances have been taken care of to get best at high quality data and particular knowledge of the market in upcoming years (forecast).. Global Transdermal Drug Delivery System Market Organizations are confronting issues in keeping their offices completely useful because of a lack of staff and assets in the midst of the COVID-19 (Coronavirus) flare-up. Get a hands-on over key drivers and menace to the Transdermal Drug Delivery System market to prepare your company ...
Description of the drug Estradot Transdermal Therapeutic System. - patient information, description, dosage and directions. What is Estradot Transdermal Therapeutic System!
Nicotine is the most commonly abused drug among individuals with schizophrenia; at least 60 percent of schizophrenics smoke cigarettes. Nicotine withdrawal may cause a temporary worsening of schizophrenia symptoms, making it especially difficult for these individuals to quit smoking. Little research has been done on the most effective way to control nicotine use in schizophrenic individuals. Transdermal nicotine and bupropion reduce smoking in non-psychiatric smokers, but little is known about the effects of these medications in smokers with schizophrenia. This project examines the effects of 0, 21 and 42 mg transdermal nicotine on smoking behavior and related subjective effects (urge to smoke and nicotine withdrawal symptoms) in smokers with schizophrenia and non-psychiatric heavy smoking controls. Participants come to the laboratory at 9 am, at which time placebo or nicotine patches are applied. After 5 hrs of smoking abstinence, participants undergo a smoking cue reactivity assessment in ...
Flector plaster is a new transdermal delivery system medicated with diclofenac hydroxyethylpyrrolidine salt, an NSAID which seems to possess suitable physiochemical properties for easy release by the plaster matrix for percutaneous absorption. The paper deals with local tolerability and pharmacokinetic (percutaneous absorption) studies carried out both on animals and on volunteers. The results obtained in the safety studies demonstrate the absence of local skin reactions and of sensitization phenomena. The kinetic evidence, obtained at the steady-state, reveals a profile typical of a sustained-release formulation, able to maintain constant plasma levels of the drug up to the next application (12 h). The amount of drug bioavailable for targeting the sites of action is effectively lower than via the oral route, however the estimated absorbed dose of 5-10 mg per application appears to be adequate for the foreseen therapeutic use, taking into account the great advantage in having no undesirable side effects
Drug delivery systems for the transdermal administration of tamsulosin are described. The systems are in the form of laminated patches having one or more reservoirs comprised of a polymeric adhesive material containing a tamsulosin formulation. The invention also relates to a method for treating benign prostatic hypertrophy (BPH) and related conditions and diseases, by administering tamsulosin transdermally, to tamsulosin-containing pharmaceutical compositions for transdermal administration of the drug and to a low-temperature method for manufacturing a tamsulosin-containing transdermal delivery system.
Transdermal drug delivery systems (TDS) are pharmaceutical devices that are designed to deliver specific drugs to the human body by diffusion through skin. The TDS effectiveness suffers from crystallization in the patch when they are kept in storage for more than two years. It has been reported that there are two types of crystals in the patch: needle and aggregate, and growth of drug crystals in TDS generally occurs only in the middle third of the polymer layer. In our study, fluorescence microscopy, EDS (SEM) and Raman microspectroscopy were used to further characterize the crystals. The results show that the needle crystals most probably contain estradiol and acrylic resin conjugate. The FTIR spectrum of the model sample proved the occurrence of a reaction between estradiol and acrylic resin. Crystal growth in an unstressed matrix of a dissolved crystallizable drug component was simulated using a kinetic Monte Carlo model. Simulation using Potts model with proper boundary condition gives the ...
Sprawdź ile zapłacisz za lek Estradot Transdermal Therapeutic System Transdermal w aptece, znajdź tańsze zamienniki leku. Określ swoje uprawnienia i sprawdź jakie zniżki Ci przysługują.
2013-2028 Report on Global Transdermal Drug Delivery System Market by Player, Region, Type, Application and Sales Channel - Radiant Insights
Transdermal drug delivery systems have grown in popularity, but side effects that include dermatitis and contact allergic reactions are possible.
Title: Liposomal Formulation for Dermal and Transdermal Drug Delivery: Past, Present and Future. VOLUME: 2 ISSUE: 1. Author(s):Mohamed I. Nounou, Labiba K. El-Khordagui, Nawal A. Khalafallah and Said A. Khalil. Affiliation:Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, 77030, USA.. Keywords:Ethosomes, transfersomes, traditional liposomes, SPLVs, MLVs, Niosomes, Catezomes, drug targeting, transdermal drug delivery, dermal drug delivery. Abstract: Although the formulation of effective topical drug delivery system is one of the most sophisticated pharmaceutical preparations, it has attracted researchers due to many medical advantages associated with it. Topical drug delivery systems can act superficially on skin surface, locally in dermal layer of the skin or transdermally to provide successful delivery of drug molecules to the systemic circulation avoiding the traditional problems and limitations of conventional routes of drug ...
Skin permeation enhancer compositions are provided which increase the permeability of skin to transdermally administered pharmacologically active agents. The composition contains diethylene glycol monoethyl or monomethyl ether in addition to an ester component such as propylene glycol monolaurate, methyl laurate or the like. The compositions are particularly useful in conjunction with the transdermal administration of steroid drugs such as progestogens and estrogens. Methods and drug delivery systems for using the enhancer compositions are provided as well.
The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(−)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino)-1-naphtol], containing a matrix for t
Fingerprint Dive into the research topics of Acute effects of transdermal administration of jojoba oil on lipid metabolism in mice. Together they form a unique fingerprint. ...
Method and therapeutic system in the form of a bandage that administer scopolamine base transdermally in an initial pulse of 10 to 200 μg/cm2 of skin that quickly brings the concentration of scopolamine in the plasma to a level at which emesis and nausea are inhibited without intolerable side effects, followed by a substantially constant dosage in the range of 0.3 to 15 μg/hr that holds said level. The bandage is a four-layer laminate of, from the top: a protective backing; a gelled, mineral oil-polyisobutene-scopolamine reservoir lamina that is the source of the constant dosage; a microporous membrane that controls the constant dosage rate; and a gelled, mineral oil-polyisobutene-scopolamine adhesive layer that is the source of the pulse dose and the means by which the bandage is attached to the skin.
METHODS: In a 12-week prospective, randomized, cross-over trial, oestradiol was administered orally in a dose of 2 mg daily or transdermally in an equivalent dose of 0.05 mg daily. Forty-five healthy early postmenopausal women were included into the study within 12 weeks after the hysterectomy and ovariectomy (surgical castration). Forty-one women completed the study and their data were analyzed. The average age was of 49+/- 6 years ...
A device and method for stabilizing a drug, particularly a chiral drug or the active enantiomer(s) thereof, in a carrier composition of a transdermal delivery system prior to the systems use by providing a product packaging system to prevent or control degradation reactions that can result from certain packaging materials and moisture contamination, while at the same time providing a child-resistant wrapping for the transdermal system.
Objective: Children with attention-deficit/hyperactivity disorder (ADHD) frequently manifest behavioral difficulties in the morning prior to school. Our aim was to examine the effects of the methylphenidate transdermal system (MTS) on before-school ADHD symptoms and functioning in children with ADHD.. Method: In this randomized crossover study, conducted from May 2007 until December 2008, 6- to 12-year-old subjects with DSM-IV-defined ADHD received either MTS or a placebo transdermal system (PTS) at 10 mg for 1 week and then 20 mg for 1 week. Subjects were then crossed over directly to the other treatment for the remaining 2 weeks. The primary efficacy measure was the ADHD Rating Scale. All analyses were intent to treat, with the last observation carried forward.. Results: Thirty subjects completed at least 1 week of treatment, and 26 subjects completed the entire protocol. The sample was primarily male, with a mean ± SD age of 9.17 ± 1.84 years. Compared to PTS, there were significant ...
Polymeric networks that retain and absorb substantial amount of water or biological fluids and resemble as a biological tissue are defined as hydrogels. On the other hand, liposomes, transfersomes and niosomes are lipid carriers, which represent one of the major research and development focus areas of the pharmaceutical industry. They have great potential as lipid vehicles that are able to enhance permeation of drugs across the intact skin and can act as local depot for the drug to sustain and control its delivery. Lipid carrier and hydrogel combinations offer transdermal drug delivery of great potential to enhance systemic effects of both hydrophilic and lipophilic drugs. Also, lipid carriers can target drugs to skin appendages and improve transdermal delivery. Lipid carrier proform systems in the form of gelly liquid crystals can also be used transdermally for better drug absorption enhancement. This review highlights the potential of hydrogels and emulgels with or without lipid nanocarriers for
Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneously. Blood draws will be done after both dosing methods in order to compare blood levels of morphine by the different routes ...
A transcutaneously implantable element in which at least a portion thereof in contact with the cutaneous tissue of a living body is composed of a ceramic material comprising, as the main raw material, at least one member selected from the group consisting of hydroxyapatite, tricalcium phosphate, and tetracalcium phosphate, and which comprises (a) an electrically conductive member for electrically connecting the interior and exterior of the living body to each other or (b) a through hole for mechanically connecting the interior and exterior of the living body to each other. This transcutaneously element can be semipermanently and safely used in a living body without causing any desirable bacterial infection, bleeding, and background noise.
According to the latest report published by Credence Research, Inc. Transdermal Skin Patches Market- (Product Type - Drug in Adhesive, Matrix, Reservoir, Vapor); (Application - Pain Relief, Nicotine Cessation, Hormone Replacement Therapy, Motion Sickness, Neurological Disorders, Cardiovascular Disorders and Others): Market Growth, Future Prospects and Competitive Analysis, 2017-2025, the market is expected to expand at a CAGR of 4.2% from 2017 to 2025.. Browse the full report at Market Insights. Transdermal drug delivery has been an attractive and challenging area of research. Advances in modern technologies are resulting in a larger number of drugs being delivered transdermally including conventional hydrophobic small molecule drugs, hydrophilic drugs and macromolecules. Transdermal delivery provides convenient and pain-free self-administration of drugs as leading to patient compliance especially in the chronic condition ...
Behavioural and pharmacological treatment for tobacco dependence typically lasts 6-12 weeks. Unfortunately, the majority of smokers relapse within 3 months of treatment. Abstinence rates at the end of treatment are consistently approximately double long-term abstinence rates (6 or 12 months after quit date and off medication), so there is considerable interest in whether we stop pharmacological treatment prematurely and whether prolonged treatment might increase long-term abstinence.. ...
The incidence and severity of local skin reactions, as well as the impact on the local bacteriologic profile, in a 7-day regimen of a matrix transdermal estradiol delivery system compared with placebo (a piece of adhesive tape for sensitive skin of approximately the same shape and area) were assessed in healthy postmenopausal Brazilian women in an open-label study. the matrix estradiol and placebo patches were applied to different sites of the abdominal area, worn for 7 consecutive days, and then replaced according to an established rotation schedule, until 5 weeks of treatment were completed. the rotation schedule was adopted to provide an assessment of skin reaction as related to (1) interval between two consecutive placements at the same application site; (2) number of repetitions; and (3) abdominal region (upper, middle, and lower). A skin reaction score was obtained at each site before the application of each patch, 80 minutes after patch removal, and 7 days after patch removal. Skin swabs ...
Finden Sie alle Bücher von Sapra, Dr. Bharti / A. K. Tiwary, Dr. - Natural Surfactants in Transcutaneous Delivery of Carvedilol.. Bei der Büchersuchmaschine können Sie antiquarische und Neubücher VERGLEICHEN UND SOFORT zum Bestpreis bestellen. 9783844399523
subcutaneous insulin infusion (CSII insulin pump).8 The study was conducted to demonstrate unambiguous therapeutic insulin levels in comparison with CSII as all subjects were required to be C-peptide negative (no endogenous insulin secretion). Subjects stopped use of long-acting insulin injection (48 hours prior) or discontinued insulin pump use prior to dosing (eight hours prior). Subjects were randomly assigned to one of two treatment arms: insulin patch applied for 12 hours followed by CSII treatment at 1.0 U/hr for 12 hours or CSII treatment at 1.0 U/hr followed by an insulin patch. In clinical use, insulin infusion basal rates are typically 0.5 U/hr to 2.0 U/hr.. The basal insulin microporation patch had an active area of 12 cm2 with 80 micropores/cm2 and contained a dry-polymer film formulation of 15 mg recombinant human insulin. The CSII treatment consisted of a Medtronic Paradigm 722 insulin pump with Humulin® R 100 U/mL (Eli Lilly). Glucose levels were clamped at 100 mg/dL which was ...
Rate controlled transdermal delivery devices are disclosed which utilize an in-line adhesive to maintain the device on the skin and deliver an agent which is a solvent or a plasticizer for the in-line adhesive. The initial equilibrated concentration of the agent in the agent reservoir and the adhesive is below saturation, and the reservoir comprises the agent dissolved in a solvent with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of the agent in reservoir is sufficient to prevent the activity of the agent in the reservoir from decreasing by more than about 50% and preferably no more than about 25% during the predetermined period of administration; and the thicknesses of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and preferably at least 75% initial equilibrated agent loading is in the reservoir layer. The devices are usable to deliver agents which are liquid at
Hormone therapy is prescribed for troublesome symptoms during menopause. While very effective in treating symptoms such as hot flashes, night sweats and mood changes, its use has declined due to safety concerns. These safety concerns became very well publicized after the 2002 report from the Womens Health Initiative study. Click here for more information.. Currently, the use of hormone therapy is still considered the gold standard for treating moderate to severe menopause symptoms. Due to safety concerns, use is generally limited to the lowest effective dose for the shortest time frame. However, women still have concerns about the potential risks associated with hormone therapy use. Fortunately, there is new research showing a potential benefit to alternative ways that hormone therapy is administered. Hormone therapy is commonly administered in an oral tablet form. However, hormones can also be delivered effectively via the skin in a transdermal patch form. Due to the manner in which the ...
Shire plc (LSE SHP, NASDAQ SHPGY), the global specialty biopharmaceutical company, announced the divestiture of Daytrana(R) (methylphenidate transdermal system)
TY - JOUR. T1 - Different effects of low-dose transdermal and oral oestrogen therapy on procarboxy-peptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: a randomised, placebo-controlled study. AU - Post, M.S.. AU - Leurs, J.R.. AU - van der Mooren, M.J.. AU - van Baal, W.M.. AU - Stehouwer, C.D.A.. AU - Kenemans, P.. PY - 2005. Y1 - 2005. M3 - Article. VL - 93. SP - 620. EP - 622. JO - Thrombosis and Haemostasis. JF - Thrombosis and Haemostasis. SN - 0340-6245. IS - 3. ER - ...
...NEW YORK April 5 2011 /- announces tha...a href href report deals with transdermal drug delivery - an approach used to...,Reportlinker,Adds,Transdermal,Drug,Delivery,-,Technologies,,Markets,,and,Companies,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
The present invention comprises a transdermal drug delivery device comprising a reservoir comprising a releasably stored dosage of a pharmaceutically active agent and a translucent film adjacent to at least a portion of the reservoir, wherein the translucent film comprises at least one inorganic ultraviolet-absorbing compound. The present invention also comprises a method of drug delivery to a mammal using such devices.
Sally Waterman, PhD, and Vasiliki Nikolaou, PhD, explain how transdermal drug delivery patches have the potential to significantly improve not only the outcome of treatments, but also the quality of life for those patients using them.
Transdermal Drug Delivery & Controlled Release Systems from Dow Corning. A World Leader in Medical Health Care Expertise & Innovative Solutions
Polymeric films of indomethacin were formulated employing ethyl cellulose and polyvinyl pyrrolidone as film formers and evaluated for transdermal admi..
Transdermal administration of hydrophobic drugs via a diffusion mechanism in which the drug is dissolved in a carrier at concentrations that are 20% to 80% of the saturation concentration. The flux of drug from the device is non-Fickian and is substantially greater than the flux observed when the drug is at saturation.
Composition of matter for application to a body surface or membrane to administer asimadoline by permeation through the body surface or membrane, the composition comprising asimadoline to be administe
Recent trends in challenges and opportunities of Transdermal drug delivery system, P.M.Patil, P.D.Chaudhari, Jalpa K.Patel, K.A.Kedar, P.P.Katolkar
The use of the fentanyl patch has also shown to be habit-forming. The transdermal patch contains potent analgesic properties, which are highly addictive. As with other forms of fentanyl, it is reserved for patients who are regular users of opiates. Those with no prior exposure to other opioid drugs are at a great risk of respiratory depression and death.. Misuse and improper application of the skin patch can also result in fatal overdose. In July 2005, the U.S. Food and Drug Administration reported that there had been hundreds of fentanyl-related deaths arising from the use of skin patches. In Florida alone, the drug was accountable for 379 deaths in the years of 2003 to 2004.. In Aiken County, South Carolina, it was reported that between January 2006 and May 2008, about 11 residents died as a direct result of the misuse of fentanyl patches.. Those who intentionally misuse or abuse the fentanyl patch for the purpose of ingesting higher doses of the drug employ methods such as: placing it in the ...
Electro-responsive Transdermal Drug Release of MWCNT/PVA Nanocomposite Hydrogels - Transdermal drug delivery;Hydrogel;Carbon nanotubes;Electro-responsive;Nanocomposite;
In the search for an optimal approach for the transcutaneous immunization (TCI) of hepatitis B surface antigen (HBsAg), two vesicle formulations, L595 vesicles (composed of sucrose-laurate ester and octaoxyethylene-laurate ester) and sPC vesicles (composed of soybean-phosphatidylcholine and Span-80) were prepared and characterized in vitro and in vivo. HBsAg was associated to the vesicles, resulting in sPC-HBsAg vesicles (+/-170nm) with 79% HBsAg association and L595-HBsAg vesicles (+/-75nm) with only 29% HBsAg association. The vesicles induced in mice via TCI an antibody response only when the skin was pretreated with microneedles. This response was improved by the adjuvant cholera toxin. The sPC-HBsAg vesicle formulations showed to be the most immunogenic for TCI, which was related to the higher degree of HBsAg association.. ...
TY - JOUR. T1 - Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting. AU - Pergolizzi, Joseph V.. AU - Philip, Beverly K.. AU - Leslie, John B.. AU - Taylor, Robert. AU - Raffa, Robert B.. PY - 2012/6. Y1 - 2012/6. N2 - Transdermal scopolamine, a patch system that delivers 1.5 mg of scopolamine gradually over 72 hours following an initial bolus, was approved in the United States in 2001 for the prevention of postoperative nausea and vomiting (PONV) in adults. Scopolamine (hyoscine) is a selective competitive anatagonist of muscarinic cholinergic receptors. Low serum concentrations of scopolamine produce an antiemetic effect. Transdermal scopolamine is effective in preventing PONV versus placebo [relative risk (RR)=0.77, 95% confidence interval (CI), 0.61-0.98, P = 0.03] and a significantly reduced risk for postoperative nausea (RR=0.59, 95% CI, 0.48-0.73, P , 0.001), postoperative vomiting (RR=0.68, 95% CI, 0.61-0.76, P , 0.001), and PONV (RR 0.73, 95% ...
Scopolamine is an alkaloid, a secondary metabolite produced by plants of nightshade family such as henbane, Datura, Duboisia, etc. Scopolamine is used to treat motion sickness, and post-operative and anesthesia induced nausea and vomiting. It is often used to treat gastrointestinal spasm, irritable bowel syndrome and eye inflammation. Scopolamine is also used for nausea and vomiting prevention in chemotherapy for cancer treatment. Scopolamine can be administered orally as tablets or syrups, intravenously as injections and solutions, or as transdermal in form of patch or gel. Transdermal scopolamine is a scopolamine patch used to treat motion sickness and post-operative nausea and vomiting. Transdermal scopolamine available today are reservoir patches which can be used for up to 3 days. These patches are applied at back side of ear. These patches are applied 20 minutes to 4 hours before the intended use such as travel, surgery etc.. The first transdermal scopolamine patch was approved in 1979, ...
Hence this study aims to formulate an anti-hypertensive drug losartan as transdermal patch using different bioadhesive polymers such as ethyl cellulose. Telmisartan Carvedilol Micardis Telmisartan 80 Mg Next day Telmisartan delivery. Transdermal Patch Telmisartan Telmisartan vs Olmesartan, Hypertension. Diclofenac Transdermal Patch: learn about side effects, dosage, HCT, in Tribenzor), telmisartan (Micardis, in Micardis HCT, in Twynsta), and.. That transdermal patch of LS with hydrophobic polymers RP: Ramipril; t1/2: Half-life; TS: Telmisartan; TTS: Transdermal therapeutic system. Nebenwirkung 80mg skin side effects telmisartan com laboratorio que fabrique benefits fungsi obat 80 mg micardis e impotenza + rhinitis transdermal patch. To improve adherence of a transdermal patch, apply an adhesive overlay cilexetil • eprosartan • irbesartan • losartan • olmesartan • telmisartan • valsartan.. ...
Appleton, Jason P. and Scutt, Polly and Dixon, Mark and Howard, Harriet and Haywood, Lee and Havard, Diane and Hepburn, Trish and England, Timothy J. and Sprigg, Nikola and Woodhouse, Lisa J. and Wardlaw, Joanna M. and Montgomery, Alan A. and Pocock, Stuart J. and Bath, Philip M.W. (2017) Ambulance-delivered transdermal glyceryl trinitrate versus sham for ultra-acute stroke: rationale, design and protocol for the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2) trial (ISRCTN26986053). International Journal of Stroke . ISSN 1747-4949 ...
GISSI-3 is a multicentre randomised clinical trial to assess the efficacy of lisinopril, transdermal glyceryl trinitrate (GTN), and their combination in improving survival and ventricular function after acute myocardial infarction (AMI). Between June, 1991, and July, 1993, 19,394 patients were rando …
The permeation of drugs through skin can be enhanced by various methods including physical methods such as iontophoresis, phonophoresis , eletroporation and by chemical penetration enhancers etc. The Transdermal route has been recognized as one of the highly potential routes of systemic drug delivery. However, the major limitation of this route is the difficulty of permeation of drug through the skin. Studies have been carried out to find safe and suitable permeation enhancers to promote the percutaneous absorption of a number of drugs. The present review highlights various categories of penetration enhancers; the involved mechanism leading to a judicious selection of suitable penetration enhancers for improving the Transdermal permeation of poorly absorbed drugs.
The aim of this study was to investigate the effect of different penetration enhancers containing essential fatty acids (EFAs) on the transdermal delivery of flurbiprofen. Flurbiprofen was used as a marker / model compound. Fatty acids were chosen as penetration enhancers for their ability to reversibly increase skin permeability through entering the lipid bilayers and disrupting their ordered domains. Fatty acids are natural, non-toxic compounds (Karande & Mitragotri, 2009:2364). Evening primrose oil, vitamin F and Pheroid™ technology all contain fatty acids and were compared using a cream based-formulation. This selection was to ascertain whether EFAs exclusively, or EFAs in a delivery system, would have a significant increase in the transdermal delivery of a compound. For an active pharmaceutical ingredient (API) to be effectively delivered transdermally, it has to be soluble in lipophilic, as well as hydrophilic mediums (Naik et al., 2000:319; Swart et al., 2005:72). This is due to the ...
Lidocaine Patch For Pain Relief Niihau, Patch Transdermal Niihau, Transdermal Drug Patch Niihau, Pain Medication Patch Form Niihau, Transdermal Medicine Niihau, Prescription Pain Patches For Your Back Niihau, Patches For Pain Relief On Prescription Niihau, Back Pain Plaster Niihau, Intradermal Patch Niihau, Medical Arm Patch Niihau, Transdermal Patch Medications Niihau, Transdermal Application Niihau, Anti Patch Pain Relief Niihau, Back Pain Patches Prescription Niihau, Transdermal Patch Drugs Niihau, Transdermal Pain Relief Niihau, Transdermal Patch Cannabis Niihau, Chronic Pain Relief Patches Niihau, Prescription Pain Patches For Chronic Pain Niihau, A Transdermal Patch Niihau, Transdermal Products Niihau, Pain Relieving Patch Prescription Niihau
The report displayed here plans showcase players to make steady progress while adequately managing one of a kind difficulties in the worldwide Estradiol Transdermal Patches advertise. The examiners and analysts creating the report have thought about different elements anticipated to emphatically and contrarily sway the worldwide Estradiol Transdermal Patches advertise. The report incorporates SWOT and PESTLE investigations to give a more profound comprehension of the worldwide Estradiol Transdermal Patches advertise. The entirety of the main organizations remembered for the report are profiled dependent on net edge, piece of the overall industry, tentative arrangements, late advancements, target client socioeconomics, items and applications, and other basic variables. The report additionally offers local examination of the Estradiol Transdermal Patches advertise with high spotlight on showcase development, development rate, and development potential. Top Players Considered in Global Builders and ...
In recent decades, pressure-sensitive adhesive (PSA) technology has evolved exponentially to offer converters more choices than ever to meet their application needs. Selecting the appropriate adhesive system can be a challenge. The application requirements and end-use environmental conditions dictate whether you use a water-based acrylic, rubber-based solvent acrylic, or silicone adhesive system. For durable, long-term applications, solvent acrylic pressure-sensitive adhesives provide the widest range of performance, including better heat, chemical, and water resistance over almost all other adhesives categories. (Silicone pressure-sensitive adhesives provide the widest . . .
0085]When a layer made from an ultraviolet curing-type pressure-sensitive adhesive that is cured by an ultraviolet in advance is adopted as the pressure-sensitive adhesive layer 14, the layer is formed as follows. That is, the pressure-sensitive adhesive layer is formed by forming a coating film by applying an ultraviolet curing-type pressure-sensitive adhesive composition onto the base material 13 and then drying the coating film (crosslinking by heating as necessary) under a prescribed condition. The coating method, the coating condition, and the drying condition can be the same as above. Further, the pressure-sensitive adhesive layer may be formed by forming a coating film by applying the ultraviolet curing-type pressure-sensitive adhesive composition onto the first separator 21 and then drying the coating film under the above-described drying condition. After that, the pressure-sensitive adhesive layer is transferred onto the base material 13. Further, the pressure-sensitive adhesive layer ...
What is Fentanyl Transdermal System nasal spray used for? Consumer medicine information. This leaflet answers some common questions about Fentanyl Transdermal System
Cross SE, Robert MS. Targeting local tissues by transdermal application: understanding drug physicochemical properties. Drug Development Res 1999;46:309-15. Finnin BC. Transdermal drug delivery-what to expect in the near future. Business Briefing Pharmatech; 2003. p. 192-3. Ghosh TK, Pfister WR. Transdermal and topical drug delivery systems. Int. Pharm, Press; 2012. p. 39. Hadgraft J, Guy R. In: Transdermal Drug Delivery. Marcel Dekker, Inc., New York and Basel; 1991. p. 296. Chein YW. Transdermal drug delivery and delivery system. In: Novel drug delivery system. Vol. 50. Marcel Dekker, Inc., New York; 1992. p. 301-81. Martin A, Swabrik J, Cammarara A. Physical pharmacy. 4th ed. New delhi: B. I Vaverly Pvt Ltd; 1996. p. 264-8. RL Cleek, AL Bunge. A new method for estimating dermal absorption from chemical exposure. General approach Pharm Res 1993;10:497â€506. Ghosh TK, Jasti BR. editors. Theory and Practice of Contemporary Pharmaceutics. 1st ed. Florida: CRC Press; 2005. p. 423-53. Roberts ...
To the Editor:. We read with interest the report of Frolich and colleagues (1) of opioid toxicity in a patient with a 3-day-old transdermal fentanyl patch in situ, undergoing surgery under lumbar epidural anesthesia and IV propofol. The opioid toxicity was related temporally to the use of a body-warming blanket to correct intraoperative hypothermia. In our study of the perioperative pharmacokinetics of transdermal fentanyl, we found that two elderly patients experienced marked respiratory depression that persisted after fentanyl patch removal. In one of these patients, plasma fentanyl concentrations were high (2.22 ng · mL− 1), and in the other, plasma concentrations were low (0.645 ng · mL− 1), but the patient had required relatively large amounts of morphine via a patient-controlled analgesia device (2). Neither of these patients was being rewarmed, but reported our concerns that transdermal absorption was variable in the perioperative period, owing to variations in cutaneous blood flow ...
Method and laminated composite for administering buprenorphine transdermally to treat pain. The composite comprises an impermeable backing layer and a reservoir layer containing buprenorphine and optionally a permeation enhancer combined with a pressure-sensitive adhesive with the amounts of buprenorphine and optional enhancer being sufficient to cause the buprenorphine to pass through the skin at a rate in excess of about 0.05 mcg/cm2 /hr.
TY - JOUR. T1 - Evaluation of Microneedles-assisted in situ Depot Forming Poloxamer gels for Sustained Transdermal Drug Delivery. AU - Khan, Samiullah. AU - Usman Minhas, Muhammad. AU - Tekko, Ismaiel A.. AU - Donnelly, Ryan F.. AU - Thakur, Raghu. PY - 2019/1/23. Y1 - 2019/1/23. N2 - In this study, for the first time, we have reported a sustained transdermal drug delivery from thermoresponsive poloxamer depots formed within the skin micropores following microneedle (MN) application. Firstly, we have investigated the sol-gel phase transition characteristics of poloxamers (PF®127, P108, and P87) at physiological conditions. Rheological measurements were evaluated to confirm the critical gelation temperature (CGT) of the poloxamer formulations with or without fluorescein sodium (FS), as a model drug, at various concentrations. Optimized poloxamer formulations were subjected to in vitro release studies using a vial method. Secondly, polymeric MNs were fabricated using laser-engineered silicone ...
Transdermal patches deliver the drug through the skin in a controlled and predetermined manner in order to increase the therapeutic efficacy of drug. Rizatriptan a 2nd generation triptan that has a favorable tolerability profile and patients have reported greater satisfaction. The aim of the present work was to formulate and evaluate transdermal patches of Rizatriptan. For the current study, the transdermal patch containing drug with different ratios of polymeric combinations and varying plasticizer concentration were prepared. The patch was fabricated by solvent casting method. The casting solvents and plasticizers used were ethanol and propylene glycol respectively. The polymers used were HPMC, PVP and EC. The fabricated patches were evaluated for its physicochemical study. From the studies it concluded that F5 (EC and HPMC of 1:4 ratio and plasticizer 2 ml) whose thickness 0.124 mm, weight variation 110 mg, folding endurance 328 times, percentage moisture absorption of 5%, tensile
Buy online GTN Transdermal Patch, We SAINTROY LIFESCIENCE are one of the ISO 9001:2008 Certified leading supplier, exporter, Manufacturer, distributor and trader of GTN Transdermal Patch based in Surat, Gujarat, India
Has your doctor prescribed a transdermal patch? A transdermal patch attaches to your skin and contains medication. They are easy to use, but to work well, they need to be used properly. Learn from step-by-step instructions and view graphics on how to apply and use a transdermal patch.
TABLE-US-00001 TABLE 1 Ex. 1 Ex. 2 Ex. 3 Ex. 4 Ex. 5 Ex. 6 Pressure-sensitive Acrylic Polymer Kinds A B B B B A Adhesive Composition Compounded Amount 100 100 100 100 100 100 Solution (parts by weight) Acrylic Oligomer Kinds a b b b b a Compounded Amount 25 25 25 25 25 25 (parts by weight) Cross-Liking Agent Kinds Colonnade Tetrad Tetrad Tetrad Tetrad Colonnade L C C C C L Compounded Amount 0.7 0.075 0.075 0.075 0.075 0.7 (parts by weight) Solid Concentration (% by weight) 27 25 25 25 25 30 Viscosity (Pa s) 1.5 1.5 1.5 1.5 1.5 1.7 Applied Thickness (μm) 45 48 36 60 40 40 Separator Ra (μm) 0.025 0.025 0.025 0.025 0.025 0.025 Substrate Presence of None None None None Present None Substrate Total Light (%) -- -- -- -- 90.2 -- Transmittance Haze Value (%) -- -- -- -- 0.8 -- Thickness of Pressure-sensitive Adhesive (μm) 12 12 9 15 10 (both 12 Layer sides) Evaluation Result Thickness Unevenness of Whole 0.014 0.014 0.012 0.018 0.025 0.019 Surface of Pressure-sensitive Adhesive Layer (μm) ...
ASIA-PACIFIC JOURNAL OF CHEMICAL ENGINEERING Asia-Pac. J. Chem. Eng. 2009; 4: 845-857 Published online 15 July 2009 in Wiley InterScience ( DOI:10.1002/apj.353 Research Article Transdermal drug delivery by coated microneedles: geometry effects on drug concentration in blood Barrak Al-Qallaf,1 Diganta Bhusan Das2 * and Adam Davidson1† 1 2 Department of Engineering Science, Oxford University, Oxford OX1 3PG, UK Department of Chemical Engineering, Loughborough University, Loughborough LE11 3TU, UK Received 22 February 2008; Revised 23 April 2009; Accepted 25 April 2009 ABSTRACT: Drug administration through transdermal delivery is restricted by the top layer of skin, the stratum corneum. One possible solution to overcome the barrier function of the stratum corneum is to employ microneedle arrays. However, detailed theoretical models relating drug-coated microneedles and their geometry to the drug concentration in the blood are limited. This article aims to address this ...
Novel drug delivery systems are now a days is creating a new interest in development of drug deliveries. Vesicular drug delivery system is also a part of these novel drug delivery systems. TDDS is the permeability of the skin, it is permeable to small molecules, lipophilic drug and highly impermeable to the macromolecules and hydrophilic drugs. Recent approaches have resulted in design of two vesicular carriers, ethosomes and ultra flexible lipid based elastic vesicles, transferosomes. Transferosomes have recently been introduced, which are capable of transdermal delivery of low as well as high molecular weight drugs. This offers several potential advantages over conventional routes like avoidance of first pass metabolism, predictable and extended duration of activity, minimizing undesirable side effects, utility of short half life drugs, improving physiological and pharmacological response and have been applied to increases the efficiency of the material transfer across the intact skin, by the use of
A transdermal therapeutic system for scopolamine (TTS-S) was developed to counter the adverse effects and short duration of action that has restricted the usefulness of scopolamine when administered o
The present invention provides pressure-sensitive adhesives having a refractive index of at least 1.50. The pressure-sensitive adhesives comprise at least one monomer containing a substituted or an unsubstituted biphenyl group.
The present invention provides pressure-sensitive adhesives having a refractive index of at least 1.50. The pressure-sensitive adhesives comprise at least one monomer containing a substituted or an unsubstituted biphenyl group.
A pressure-sensitive adhesive sheet material for delivering estradiol to skin, the sheet material comprising a backing with a layer of a pressure-sensitive adhesive adjacent thereto, said pressure-sensitive adhesive layer comprising a pressure-sensitive adhesive polymer, two or more skin penetration-enhancing ingredients and estradiol. The sheet material is useful for systemic treatment of conditions associated with estradiol deficiency. Methods of using such adhesive sheet material are also described.
The purpose of this study is to establish the clinical utility and safety of fentanyl TTS (a transdermal patch delivering the narcotic pain reliever fen
Introduction: While nitroglycerin (NTG) is often used in the treatment of CHF it is not formally approved for that purpose. Whether addition of low dose NTG is of value in patients already on guideline-based therapy (ACE inhibitors, beta-blockers, diuretics) is not known, nor is it known whether response to NTG added to these medicines varies with severity of left ventricular dysfunction.. Methods: Exercise capacity by six-minute walk test (6MWT), quality of life by the Minnesota Living with Heart Failure Questionnaire (HFQ), and ejection duration (ED) by Sphygmocor© were measured at baseline and after a 4 week course of transdermal NTG, given at 0.2 mg/hr for 12 hours daily. We studied 45 NYHA Class II and III patients (84% male, 53.4 ± 9.1 yrs, 42% with CAD, CHF duration 3 ± 2.6 yrs, LVEF ≤40%) on stable, standard, guideline-based CHF therapy. ED was defined in msec from the foot to the incisura of the applanation tonometry derived radial artery pressure waveform.. Results: Subjects were ...
Compare Minitran transdermal patch (nitroglycerin) 0.4 mg prices from verified online pharmacies or local U.S. pharmacies. Print free coupons for Minitran transdermal patch, shop safely and save money on your prescription medication costs today.
Compare Minitran transdermal patch (nitroglycerin) 0.4 mg prices from verified online pharmacies or local U.S. pharmacies. Print free coupons for Minitran transdermal patch, shop safely and save money on your prescription medication costs today.
Abstract Objectives: Transdermal drug delivery suggests several advantages and has been vastly investigated over last decades.Chemical enhancers improve the quantity of drug penetration through the skin. In this study, hydrophilic solvents have been used as enhancers to promote dermal penetration of albumin.. Methods: 20 different formulations containing albumin and hydrophilic solvents were prepared. Transdermal absorption experiments for each formulation were performed using a diffusion cell and a slice of chicken skin as model at 32°C for 3 hours. Samples from the medium were withdrawn and analyzed for albumin concentration. Cumulative amounts of albumin were plotted for each formulation.. Results: After3 hours, 6.8, 5.8, 69.0, 7.9, 11.1, 25.2, 32.0, 98.0, 21.3 and 74.3 mg of albumin were passed through the skin, using formulations containing deionized water (DW), acetic acid, ethyl acetate (EA), methanol, ethanol, 2-propanol, isopropyl alcohol (IPA), glycerol, ethylene glycol (EG) and ...
To provoke an immune response, a transcutaneously administered vaccine has to diffuse into the skin, reach the lymph nodes and be taken up by dendritic cells (DCs). To study these three steps we immunised mice transcutaneously (with microneedles), intradermally and intranodally. The effect of the formulation was investigated by formulating ovalbumin (OVA) in three ways with N-trimethyl chitosan (TMC): TMC+OVA mixtures, TMC-OVA conjugates and TMC/OVA nanoparticles. Both the percentage OVA(+) DCs in the lymph node and the resultant immunogenicity (serum IgG titres) were studied. Transcutaneously, the TMC-OVA conjugates induced the highest IgG levels and resulted in more OVA(+) DCs in the lymph nodes after 24h than the other TMC formulations. Intradermally, all TMC-adjuvanted OVA formulations increased IgG titres compared to plain OVA. These formulations formed a depot in the skin, prolonging OVA delivery to the lymph nodes. The prolonged delivery of TMC-adjuvanted OVA to lymph node resident DCs ...
APRIL 19, 2019 Alvogen, Inc. is voluntarily recalling two lots of Fentanyl Transdermal System 12 mcg/h transdermal patches to the consumer level. A small number of cartons labeled 12 mcg/h Fentanyl Transdermal System patches contained 50 mcg/h patches. The 50 mcg/h patches that were included in cartons labeled 12 mcg/h are individually labeled as 50 mcg/h. This transdermal
Read Handbook of Formulating Dermal Applications A Definitive Practical Guide by with Rakuten Kobo. The conceptualization and formulation of skin care products intended for topical use is a multifaceted and evolving area...
A case of accidental poisoning of an adult by the misuse of an organophosphorous insecticide solution Neguvon is presented. Repeated dermal application of the compound produced moderate symptoms and the fall of the erythrocyte (56%) and...
Pain Research and Treatment is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical focusing on laboratory and clinical findings in the field of pain research and the prevention and treatment of pain. The journal welcomes submissions in the areas of chronic pain, anaesthesia, dentistry and oral medicine, rheumatology, and drug development.
Title:Advanced Drug Delivery Systems for Transdermal Delivery of Non-Steroidal Anti-Inflammatory Drugs: A Review. VOLUME: 15 ISSUE: 8. Author(s):Lalit Kumar, Shivani Verma, Mehakjot Singh, Tammana Chalotra and Puneet Utreja*. Affiliation:Faculty of Pharmaceutical Sciences, Department of Pharmaceutics, PCTE Group of Institutes, Ludhiana, Punjab 142021, I. K. Gujral Punjab Technical University, Jalandhar-Punjab 144601, Faculty of Pharmaceutical Sciences, Department of Pharmaceutics, PCTE Group of Institutes, Ludhiana, Punjab 142021, Faculty of Pharmaceutical Sciences, Department of Pharmaceutics, PCTE Group of Institutes, Ludhiana, Punjab 142021, Faculty of Pharmaceutical Sciences, Department of Pharmaceutics, PCTE Group of Institutes, Ludhiana, Punjab 142021. Keywords:Dendrimer, liposomes, nanocarrier, nanofibers, transdermal, niosomes, ethosomes.. Abstract:Background: Transdermal route of delivery of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) has several advantages over other routes like ...
Jan. 11, 2018 /PRNewswire/ -- Global Hypodermic Needles Market by Product Type {Safety Hypodermic Needles, by Type (Retractable Needles, Non-retractable Needles) and Safety Hypodermic Needles, by Mode of Activation (Active Needles and Passive Needles), Non-Safety Hypodermic Needles}, Application (Drug Delivery, Vaccin.....
December 2012). "Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in ... some to suggest that cutaneous melanin might somehow serve to protect the neuromelanin in substantia nigra from external toxins ... vivo". Cutaneous and Ocular Toxicology. 31 (4): 312-7. doi:10.3109/15569527.2012.676119. PMID 22515841. S2CID 30344869. King G ...
Shaw, LA (1928). "Cutaneous Respiration of the Cat". American Journal of Physiology. 85 (1): 158-67. doi:10.1152/ajplegacy. ... A Design for Small Children and Infants with an Appliance for the Administration of Oxygen and Carbon Dioxide". J Clin Invest. ... Shaw, LA; Drinker, P (1929). "AN APPARATUS FOR THE PROLONGED ADMINISTRATION OF ARTIFICIAL RESPIRATION: I. A Design for Adults ... Drinker, P; Shaw, LA (1932). "The prolonged administration of artificial respiration". Journal of the Franklin Institute. 213 ( ...
"国家食品药品监督管理总局关于停止生产销售使用酮康唑口服制剂的公告(2015年第85号)" (in Chinese). China Food and Drug Administration. 25 June 2015. Archived from the ... Gupta AK, Lyons DC (2015). "The Rise and Fall of Oral Ketoconazole". Journal of Cutaneous Medicine and Surgery. 19 (4): 352-7. ... Applied to the skin it is used for fungal skin infections such as tinea, cutaneous candidiasis, pityriasis versicolor, dandruff ... U.S. Food and Drug Administration. 26 July 2013. Archived from
"Spevigo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 2 September 2022. "U.S. FDA approves first ... Journal of Cutaneous Medicine and Surgery. 24 (2): 199-200. doi:10.1177/1203475419888862. PMID 32208020. S2CID 214641620. " ...
SJS and TEN most often begin between 4 and 28 days after culprit drug administration. A published algorithm (ALDEN) to assess ... All three are part of a spectrum of severe cutaneous reactions (SCAR) which affect skin and mucous membranes. The distinction ... Severe Cutaneous Adverse Reactions (2002). "Correlations between clinical patterns and causes of Erythema Multiforme Majus, ... Su SC, Hung SI, Fan WL, Dao RL, Chung WH (2016). "Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to ...
Alternatives to oral administration have been studied. Terbinafine may induce or exacerbate subacute cutaneous lupus ... The U.S. Food and Drug Administration has approved the first generic versions of prescription Lamisil (terbinafine ... Callen JP, Hughes AP, Kulp-Shorten C (September 2001). "Subacute cutaneous lupus erythematosus induced or exacerbated by ... "PI and CMI Trade Names and Active Ingredients containing Terbinafine". Therapeutic Goods Administration. Australian Government ...
Tissue and systemic diffusion of idrocilamide after cutaneous administration]". Revue du Rhumatisme (in French). 60 (12): 932-6 ...
Infection caused by cutaneous larvae migrans, a skin disease in humans, is characterized by skin ruptures and severe itching. ... "Clinical Aspects and Treatment of the More Common Intestinal Parasites of Man (TB-33)". Veterans Administration Technical ... Cryotherapy by application of liquid nitrogen to the skin has been used to kill cutaneous larvae migrans, but the procedure has ... S2CID 19551476.{{cite journal}}: CS1 maint: uses authors parameter (link) Caumes, Eric (2000). "Treatment of Cutaneous Larva ...
medicine portal List of cutaneous conditions Steroid acne Freedberg, et al. (2003). Fitzpatrick's Dermatology in General ... Steroid folliculitis occurs following administration of glucocorticoids or corticotropin. Other medications can also mimic ...
In June 2018, it was approved for the treatment of certain melanomas by the U.S. Food and Drug Administration (FDA) in ... Koelblinger P, Dornbierer J, Dummer R (August 2017). "A review of binimetinib for the treatment of mutant cutaneous melanoma". ... "Drug Trial Snapshot: Mektovi". U.S. Food and Drug Administration (FDA). 19 December 2019. Archived from the original on 19 ... Food and Drug Administration (FDA). 27 June 2018. Archived from the original on 19 December 2019. Retrieved 17 July 2018. This ...
Additionally the administration of more dose intensive epirubicin-containing regimens to patients with metastatic breast cancer ... Reversible alopecia and local cutaneous reactions are important adverse effects too. Those could be related with radiation ... are 1.3 to 1.7 times higher for doxorubicin than epirubicin following single-dose intravenous administration. Epirubicin shows ... of patients without a right prophylactic antiemetics therapy experience nausea and vomiting the first 24 h after administration ...
From 1962 to 1964 he was a resident in dermatology and syphilology at the Bronx Veterans Administration Hospital in New York. ... 1990 American College of Mohs Micrographic Surgery and Cutaneous Oncology: Board Certification. In 1978 Perry founded the Skin ...
List of cutaneous conditions Reference, Genetics Home. "Sézary syndrome". Genetics Home Reference. Sézary's cell at Who Named ... "FDA approves mogamulizumab-kpkc for mycosis fungoides or Sézary syndrome". U.S. Food and Drug Administration. 2018-08-08. ... Sézary disease, or Sézary syndrome, is a type of cutaneous T-cell lymphoma that was first described by Albert Sézary. The ... Romidepsin, vorinostat and a few others are a second-line drug for cutaneous T-cell lymphoma. Mogamulizumab has been approved ...
"Miltefosine (Impravido) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis" (PDF). Food and Drug Administration ... Soto J, Berman J (2006). "Treatment of New World cutaneous leishmaniasis with miltefosine". Trans R Soc Trop Med Hyg. 100: S34- ... However, priority was given to the development of the compound for cutaneous metastases of breast cancer. In 1992 a new ... This includes the three forms of leishmaniasis: cutaneous, visceral and mucosal. It may be used with liposomal amphotericin B ...
In July 2009, the U.S. Food and Drug Administration (FDA) approved cetuximab (Erbitux) for treatment of colon cancer with wild- ... Nguyen A, Hoang V, Laquer V, Kelly KM (December 2009). "Angiogenesis in cutaneous disease: part I". Journal of the American ... Cetuximab was approved by the US Food and Drug Administration (FDA) in March 2006, for use in combination with radiation ... In July 2009, the US Food and Drug Administration (FDA) updated the labels of two anti-EGFR monoclonal antibody drugs ( ...
List of cutaneous conditions McKnight JT, Maxwell AJ, Anderson RL (1992). "Warfarin necrosis". Arch Fam Med. 1 (1): 105-8. doi: ... These include gradual increase starting from low doses and supplemental administration of protein C (pure or from fresh frozen ... Since the clot-promoting effects of starting administration of 4-hydroxycoumarins are transitory, patients with protein C ...
It shortens the course of cutaneous disease and may protect against its dissemination. Varicella zoster virus is a human herpes ... This medication is not recommended for administration to immune-competent persons for the treatment of active disease. The ...
Food and Drug Administration (FDA) therapy for cutaneous T-cell lymphoma. Evidence suggests that this treatment might help ... "Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results". New England Journal of ...
In 1999, Ontak was approved by the U.S. Food and Drug Administration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL). ... "FDA Drug Shortages". U.S. Food and Drug Administration. 31 January 2014. Retrieved 3 July 2017. FDA Safety Alert v t e ( ... "Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma". Cancer Management and ...
Virus-related cutaneous conditions, Cutaneous conditions, Viral diseases, Wikipedia medicine articles ready to translate, ... It has been approved by the U.S. Food and Drug Administration (FDA) for genital warts. Cantharidin, found naturally in the ... Kwok CS, Gibbs S, Bennett C, Holland R, Abbott R (12 September 2012). Gibbs S (ed.). "Topical treatments for cutaneous warts". ... Sterling JC, Handfield-Jones S, Hudson PM (2001). "Guidelines for the management of cutaneous warts" (PDF). British Journal of ...
AK with cutaneous horn: A cutaneous horn is a keratinic projection with its height at least one-half of its diameter, often ... "Klisyri: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 15 December 2020. "NDA APPROVAL" (PDF). U.S. ... 38-40% of cutaneous horns represent AKs. Pigmented AK: Pigmented AKs are rare variants that often present as macules or plaques ... Kim JY, Kozlow JH, Mittal B, Moyer J, Olenecki T, Rodgers P (March 2018). "Guidelines of care for the management of cutaneous ...
Fåhraeus L, Larsson-Cohn U (December 1982). "Oestrogens, gonadotrophins and SHBG during oral and cutaneous administration of ... With oral administration of estradiol, the ratio of estradiol levels to estrone levels is about 5 times higher on average than ... Oral administration of menopausal replacement dosages of estradiol results in low, follicular phase levels of estradiol, ... Selby P, McGarrigle HH, Peacock M (March 1989). "Comparison of the effects of oral and transdermal oestradiol administration on ...
Understanding Drug Incorporation and Delivery from Biocompatible Metal-Organic Frameworks in View of Cutaneous Administration ...
Fåhraeus L, Larsson-Cohn U (December 1982). "Oestrogens, gonadotrophins and SHBG during oral and cutaneous administration of ... With oral administration of estradiol, the ratio of estradiol levels to estrone levels is about 5 times higher on average than ... Oral administration of menopausal replacement dosages of estradiol results in low, follicular phase levels of estradiol, ... In these studies, prior to administration of estrone, amenorrhea, atrophy of the breasts (as well as flaccidity and small and ...
"Table of Pharmacogenomic Biomarkers in Drug Labels". U.S. Food and Drug Administration. "Tumor Markers Fact Sheet" (PDF). ... "Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome". American ...
In September 2018, it was approved by the U.S. Food and Drug Administration (FDA) for treating people with metastatic cutaneous ... "FDA approves first treatment for advanced form of the second most common skin cancer". U.S. Food and Drug Administration. 28 ... New PD-1 Inhibitor OK'd for Cutaneous SCC - Sixth PD-1/PD-L1 checkpoint inhibitor approved by agency 2018 "Isatuximab in ... Lee A, Duggan S, Deeks ED (June 2020). "Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma". Drugs. 80 (8): 813 ...
The routes of administration vary. They may be both systemic and topical. For example, pseudoephedrine is taken orally and ... Cutaneous vasoconstriction will occur because of the body's exposure to the severe cold. Examples of endogenous factors include ...
On occasion,[which?] serum levels of the drug can be identified from oral, vaginal, or cutaneous administration, and lead to ...
... have been studies demonstrating that topical administration of mechlorethamine has efficacy in mycosis fungoides-type cutaneous ... Bunn Jr, P. A.; Hoffman, S. J.; Norris, D; Golitz, L. E.; Aeling, J. L. (1994). "Systemic therapy of cutaneous T-cell lymphomas ... Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the ... Nitrogen mustards HN1 HN3 "Ledaga". Therapeutic Goods Administration (TGA). 30 June 2021. Retrieved 5 September 2021. "Ledaga ...
... have entered clinical trials against tumor growth but have yet to be approved by Food and Drug Administration (FDA). A ... recombinant diphtheria exotoxin has been approved by the FDA for treatment of cutaneous T-cell lymphoma, an immune system ...
Démarchez, M. «Cutaneous nervous system» (en anglès). Biologie de la peau, 07-05-2010. [Consulta: 24 agost 2015]. ... A Case Report on a Rare but Serious Debilitating Side-Effect of Fluoroquinolone Administration» (en anglès). J Investig Med ... Mendonca DA, Staiano JJ, Drew PJ «An unusual cutaneous neuroma following a burn injury» (en anglès). J Plast Reconstr Aesthet ...
The administration of intravenous immunoglobulins (IVIGs) has had some success in treating neutropenias of alloimmune and ... mucociliary and cutaneous barriers; a rapid decline in absolute neutrophil count, duration of neutropenia ,7-10 days, and other ... reduce the occurrence of chemotherapy-induced neutropenia and the associated need for interventions such as the administration ...
"Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a ...
National Oceanographic and Atmospheric Administration. Archived from the original on 3 January 2017.. ... "A comparison of UVb compact lamps in enabling cutaneous vitamin D synthesis in growing bearded dragons". Journal of Animal ...
Southall, H. Cutaneous Tuberculosis Symptoms [online]. [cit. 2011-07-12]. Dostupné v archivu pořízeném dne 2011-05-03. ... Dietrich, J., Andersen, C., Rappuoli, R., Doherty, T. M., Jensen, C. G., Andersen, P. Mucosal Administration of Ag85B-ESAT-6 ...
List of cutaneous conditions Linezolid Tedizolid SSTI is the preferred description of the Infectious Diseases Society of ... The U.S. Food and Drug Administration began referring to this category of infection as acute bacterial SSSIs (ABSSSI) in 2008. ... Food and Drug Administration. October 2013. Retrieved 2014-11-23. Xia, Fan Di; Song, Philip; Joyce, Cara; Mostaghimi, Arash ( ... Food and Drug Administration. Aug 2010. Rosen, T (2005). "Update on treating uncomplicated skin and skin structure infections ...
Administration of Type I IFN has been shown experimentally to inhibit tumor growth in animals, but the beneficial action in ... and cutaneous T-cell lymphoma. Patients with recurrent melanomas receive recombinant IFN-α2b. Both hepatitis B and hepatitis C ... For example, in January 2001, the Food and Drug Administration (FDA) approved the use of PEGylated interferon-alpha in the USA ...
Ointments, gels, creams or dusting powder may be used when patients develop cutaneous lesions. Skin irritations may occur in ... Nystatin is the only polyene antifungal that is available for topical administration. The drug is derived from Streptomyces ... They can also be used for the treatment of cutaneous candidiasis and pityriasis versicolor. The medication is sometimes ... Benitez, Lydia L.; Carver, Peggy L. (2019-06-01). "Adverse Effects Associated with Long-Term Administration of Azole Antifungal ...
... without signs of candidiasis on other mucosal or cutaneous sites. The lesions are variably red and/or white. Unusually for ... depending on the route of administration. Topically administered corticosteroids in the mouth may take the form of mouthwashes ... Mycosis-related cutaneous conditions, Oral mucosal pathology, Fungal diseases). ...
Intravenous administration of ceftriaxone is recommended as the first choice in these cases; cefotaxime and doxycycline are ... Bacterium-related cutaneous conditions, Medical controversies, Neurodegenerative disorders, Wikipedia medicine articles ready ... It was granted fast track designation by the U.S. Food and Drug Administration in July 2017. In April 2020 Pfizer paid $130 ... On 21 December 1998, the Food and Drug Administration (FDA) approved LYMErix on the basis of these trials for persons of ages ...
Based on this study, the Food and Drug Administration approved ibrutinib for use in Waldenström macroglobulinemia in 2015. ... Vascular-related cutaneous conditions). ... Food and Drug Administration (FDA). 1 September 2021. Retrieved ...
Immunotherapy, administration of human neutralizing antibodies during acute phases of hantavirus, has been studied only in mice ... hantavirus outbreak Bat-borne virus Cocoliztli epidemics Conjunctival suffusion Limestone Canyon virus List of cutaneous ...
ISBN 9780815173120 Atlas of Cutaneous Surgery (1996) ISBN 9780721654041 Cutaneous Medicine and Surgery: An Integrated Program ... She has been associated with Lakeside Veterans Administration Hospital, Foster McGaw Hospital at Loyola University Medical ...
"Cutaneous T-cell lymphoma - Diagnosis and treatment - Mayo Clinic". Retrieved 2020-04-08. "National ... Pralatrexate is the first approved drug to treat lymphoma by the Food and Drug Administration (FDA) in 2009. It is shown to ... Less common subtypes of mature T-cell lymphoma include cutaneous T-cell lymphoma, adult T-cell leukaemia/lymphoma, enteropathy- ... Extracorporeal photopheresis (ECPP) is mainly used to treat cutaneous T-cell lymphoma. White blood cells are removed from the ...
Prompt administration of appropriate antibiotics decreases the length of illness. Peeling of the outer layer of skin, however, ... Bacterium-related cutaneous conditions, Pediatrics, Rare diseases, Rare infectious diseases, Wikipedia emergency medicine ...
He wrote also: An Essay on the Theory and Production of Animal Heat, and on its Application in the Treatment of Cutaneous ... In 1783 Rigby became a member of the corporation of guardians of Norwich, and promoted the economical administration of the ...
Mal morando This cutaneous condition is characterized by inflammation accompanied by hyperpigmentation.: 440 Sowda A cutaneous ... In mass drug administration (MDA) programmes, the treatment for onchocerciasis is ivermectin (trade name: Mectizan); infected ... The key factor in elimination is mass administration of the antiparasitic drug ivermectin. The initial projection was that the ... Abiose, Adenike (March 1993). "A clinical classification and grading system of the cutaneous changes in onchocerciasis". ...
Impaired vasodilation of cutaneous blood vessels may occur as part of type 2 diabetes. Where ambient temperatures are high, ... In the field of oncology, 'hyperthermia' refers to treatment of malignant diseases by administration of heat to the body to a ... Common modalities of cryotherapy often include administration of ice packs or frozen peas to the affected area, or even ... Hensel, Herbert (1973), "Cutaneous Thermoreceptors", Somatosensory System, Handbook of Sensory Physiology, vol. 2, Springer ...
The US Food and Drug Administration (FDA) requires the companies marketing the drug to put this website in place as a risk ... Brelsford M, Beute TC (September 2008). "Preventing and managing the side effects of isotretinoin". Seminars in Cutaneous ... Three metabolites of isotretinoin are detectable in human plasma after oral administration: 4-oxo-isotretinoin, retinoid acid ( ... "FDA information, side effects, and uses / Accutane (isotretinoin)". U. S. Food and Drug Administration (FDA). Retrieved 20 ...
Lynn B (1984). "Cutaneous nociceptors". In Winlow W, Holden AV (eds.). The neurobiology of pain: Symposium of the Northern ... The administration of torture on bodies othered by the cultural narrative, those observed as not 'full members of society' : ... and they produce progressively weaker effects with repeated administration.: 26-8 It is possible for many with chronic pain to ...
Single-dosage administrations of liposomal amphotericin B have been shown to be effective, and oral formulations are currently ... This disease is not the same as cutaneous leishmaniasis, a milder disease caused by another protozoan of the Leishmania genus ... "Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of ...
It is an option for both visceral leishmaniasis and cutaneous leishmaniasis. Pentamidine can be given by injection into a vein ... To avoid side-effects associated with intravenous administration, the solution should be slowly infused to minimize the release ... Food and Drug Administration Use as an antitumor drug has also been proposed. Pentamidine is also identified as a potential ...
"Drug Approval Package: Abreva (Docosanol) NDA #20-941". U.S. Food and Drug Administration (FDA). 21 August 2001. Retrieved 13 ... and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection". Archives of Dermatology. 137 (9): ...
Rubin LG, Lanzkowsky P. Cutaneous neonatal herpes simplex infection associated with ritual circumcision. Pediatric Infectious ... "Generalized seizures following topical lidocaine administration during circumcision: establishing causation". Paediatr Drugs. 9 ...
Kochi had been replaced, the WHO recommended the co-administration of the antimalarial drug sulfadoxine pyrimethamine with ... notably the cutaneous reactions that stopped the use of sulfadoxine pyrimethamine as prophylaxis. An added theoretical concern ... IPTp consists in the administration of a single curative dose of an efficacious anti-malarial drug at least twice during ... treatment effect seen in mass drug administrations) and to prevent new infections (prophylaxis).[citation needed] IPTi using ...
US Food and Drug Administration, June 21, 2007". Food and Drug Administration. Boulton F. The 13% rule. Comments. Transfusion ... Lipoprotein(a) (Lp(a) apheresis Photopheresis - used to treat graft-versus-host disease, cutaneous T-cell lymphoma, and ... "Recall of Amicus Apheresis Kits, Baxter Healthcare Corporation". Food and Drug Administration. Archived from the original on ...
Administration of pre-natal dexamethasone has been the subject of controversy over issues of informed consent and because ... Endocrine-related cutaneous conditions, Intersex variations). ...
Filice, C; Brunetti, E; DAndrea, F; Filice, G; World Health Organization. Schistosomiasis and Intestinal Parasites Unit; World Health Organization. Division of Control of Tropical Diseases (‎World Health OrganizationWorld Health Organization, 1997)‎ ...
... including cutaneous T cell lymphoma. During extracorporeal photopheresis, peripheral blood is removed from the patient and the ... including cutaneous T cell lymphoma. During extracorporeal photopheresis, peripheral blood is removed from the patient and the ...
To provide oral agents for development targeting cutaneous leishmaniasis, we have implemented a discovery scheme that ... Cutaneous leishmaniasis is clinically widespread but lacks treatments that are effective and well tolerated. Because all ... Tier 1b: in vivo mouse treatment test with intraperitoneal drug administration.. Intraperitoneal drug administration for the ... Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 51: 409-419. ...
Drug administration. Lip-AmB 0.4% was produced under good manufacturing practice conditions at Razaak Arak Pharmaceutical ... Cutaneous leishmaniasis is the most common form of leishmaniasis and it is endemic in about 90 countries, with 600 000 to 1 ... Cutaneous leishmaniasis is a major public health threat in some endemic areas, with 600 000 to 1 million new cases worldwide ... Cutaneous leishmaniasis causes skin lesions with various clinical features from slow-healing lesions to permanent scars (3), ...
Describes a means by which cutaneous carbon dioxide (PcCO2) and oxygen (PcO2) monitor devices may comply with the requirement ... Food and Drug Administration. Center for Devices and Radiological Health. Anesthesiology and Respiratory Devices Branch. ... The cutaneous PO2 reading should not drift by more than 5% of the initial reading over the specified calibration interval. You ... Cutaneous Oxygen (PcO2) Monitor. (21 CFR 868.2500, Product Code 73 LPP, for uses other than for infant not under gas anesthesia ...
J. Appl. Cosmetol. 6, 31-36 (January-March 1988) T. DE ANGELIS, G. MORETTI , G. PARISI, G. SALVATORE
To provide oral agents for development targeting cutaneous leishmaniasis, we have implemented a discovery scheme that ... Cutaneous leishmaniasis is clinically widespread but lacks treatments that are effective and well tolerated. Because all ... Tier 1b: in vivo mouse treatment test with intraperitoneal drug administration.. Intraperitoneal drug administration for the ... Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 51: 409-419. ...
... is an aggressive cutaneous neuroendocrine carcinoma without a known dysplastic precursor. In some cases, MCC is associated with ... Project Administration: C.L., A.M.U., A.A.D.; Resources: M.P.C., R.M.P., A.M.U., A.A.D.; Software: K.H., A.M.U.; Supervision: C ... Cutaneous basal cell carcinosarcomas: evidence of clonality and recurrent chromosomal losses. Hum. Pathol. 46, 690-697 (2015). ... Harms, P.W., Verhaegen, M.E., Hu, K. et al. Genomic evidence suggests that cutaneous neuroendocrine carcinomas can arise from ...
The ulcer became larger despite administration of oral erythromycin and dicloxacillin. On February 20, the student was admitted ... Cutaneous Leishmaniasis -- Ohio On January 19, 1985, a 23-year-old male graduate student in Ohio noted an ulceration on his ... Three species of cutaneous Leishmania are seen in the Americas. Ulcers caused by L. peruviana or L. mexicana may heal ... Old World cutaneous leishmaniasis is similarly widespread from the Union of Soviet Socialist Republics through the Middle East ...
Administration of Drugs. The drugs tested were injected (using a 30-gauge needle) subcutaneously in unanesthetized rats under ... Enhancement of Cutaneous Analgesia by Epinephrine. The enhancement of cutaneous analgesia elicited by amitriptyline by the ... Amitriptyline Is Applicable for Prolonged Cutaneous Analgesia. We have shown that the duration of cutaneous analgesia (i.e. , ... In keeping with the objective of identifying drugs for prolonged cutaneous analgesia, the authors compared the cutaneous ...
Cutaneous Renal and Glomerular Vasculopathy (CRGV) or Alabama Rot in dogs 27 March 2018. There have been further reports of ... Cutaneous Renal and Glomerular Vasculopathy (CRGV) or Alabama Rot in dogs, is typically characterized by ulceration or erosions ...
Adjuvants, Immunologic / administration & dosage* * Adjuvants, Immunologic / adverse effects * Administration, Cutaneous * ...
Influence of estrogen administration on tumor characteristics and survival in women with cutaneous melanoma. J Natl Cancer Inst ... Guidelines on cutaneous melanoma management and systemic therapy for metastatic or unresectable cutaneous melanoma and ... encoded search term (Cutaneous Melanoma) and Cutaneous Melanoma What to Read Next on Medscape ... Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004 Dec 8. 292(22):2771-6. [QxMD MEDLINE Link]. ...
Bacterial cultures remained negative, presumably because of previous administration of antimicrobial drugs. The clinical ... In cutaneous anthrax, antibodies to protective antigen develop in 68%-92% of cases (6,7). Previous cases of cutaneous anthrax ... Irmak H, Buzgan T, Karahocagil MK, Sakarya N, Akdeniz H, Caksen H, Cutaneous manifestations of anthrax in Eastern Anatolia: a ... Maguina C, Flores Del Pozo J, Terashima A, Gotuzzo E, Guerra H, Vidal JE, Cutaneous anthrax in Lima, Peru: retrospective ...
... with factors related to administration, insufficient health infrastructure and coverage, and (3) CL treatment, which covers ... such as cutaneous leishmaniasis (CL) are often associated with rural territories and vulnerable communities with limited access ... Barriers to cutaneous leishmaniasis care faced by indigenous communities of rural areas in Colombia: a qualitative study. * ... Barriers to cutaneous leishmaniasis care faced by indigenous communities of rural areas in Colombia: a qualitative study ...
HRT administration may be effective in SSc post-menopausal women, preventing the development of iPHT. ... Conclusion: HRT administration may be effective in SSc post-menopausal women, preventing the development of iPHT. ... Methods: A retrospective cohort study was conducted on 61 SSc patients with the limited cutaneous form of the disease and no ... In many animal and human models, hormone replacement therapy (HRT) and oestrogen administration proved efficacious in ...
Veterans Administration Medical Center of Seattle. Gregory J Raugi, MD, PhD is a member of the following medical societies: ... encoded search term (Cutaneous Manifestations of Cholesterol Embolism) and Cutaneous Manifestations of Cholesterol Embolism ... Cutaneous Manifestations of Cholesterol Embolism Medication. Updated: Aug 26, 2021 * Author: Laura F McGevna, MD; Chief Editor ... The cutaneous manifestations of cholesterol crystal embolization. Arch Dermatol. 1986 Oct. 122(10):1194-8. [QxMD MEDLINE Link] ...
Influence of estrogen administration on tumor characteristics and survival in women with cutaneous melanoma. J Natl Cancer Inst ... encoded search term (Cutaneous Melanoma) and Cutaneous Melanoma What to Read Next on Medscape ... Cutaneous Melanoma Differential Diagnoses. Updated: Mar 22, 2022 * Author: Susan M Swetter, MD; Chief Editor: Dirk M Elston, MD ... Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004 Dec 8. 292(22):2771-6. [QxMD MEDLINE Link]. ...
5.2 New Primary Cutaneous Malignancies In INVICTUS, cutaneous squamous cell carcinoma (cuSCC) occurred in 4.7% of the 85 ... 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage 2.2 Dosage Modifications for Adverse Reactions 2.3 Dose Modifications for ... 5.2 New Primary Cutaneous Malignancies 5.3 Hypertension 5.4 Cardiac Dysfunction 5.5 Risk of Impaired Wound Healing 5.6 ... Dosage and Administration Instruct patients to take QINLOCK at the same time each day (once daily) with or without food. Advise ...
Route of Administration. CUTANEOUS. DEA Schedule. Active Ingredient/Active Moiety. Ingredient Name. Basis of Strength. Strength ... DOSAGE AND ADMINISTRATION. Apply lidocaine patch 5% to intact skin to cover the most painful area. Apply the prescribed number ... Lidocaine overdose from cutaneous absorption is rare, but could occur. If there is any suspicion of lidocaine overdose (see ... The half-life of lidocaine elimination from the plasma following IV administration is 81 to 149 minutes (mean 107 ± 22 SD, n = ...
Belosevic, M., Finbloom, D. S., Van Der Meide, P. H., Slayter, M. V., Nacy, C. A. (1989). Administration of monoclonal anti-IFN ... 2013). Cutaneous and post kala-azar dermal leishmaniasis caused by Leishmania infantum in endemic areas of visceral ... Immunomodulation From Moderate Exercise Promotes Control of Experimental Cutaneous Leishmaniasis. Rodrigo Terra1†, Pedro J. F. ... Von Stebut, E. (2007). Cutaneous Leishmania infection: progress in pathogenesis research and experimental therapy. Exp Dermato. ...
Could you recognize the cutaneous manifestations of 10 relatively rare systemic diseases? ... Rutgers University School of Public Affairs and Administration. Newark, NJ. Disclosure: Robert A. Schwartz, MD, MPH, has ... but topical or intralesional corticosteroids may be used for limited cutaneous lesions. Other potential therapies for cutaneous ... Cutaneous involvement may have a variety of presentations and occurs in approximately 25% of patients[14] (granulomatous skin ...
It was approved by the United States Food and Drug Administration (FDA) in 2006 for the treatment of head and neck cancer. ... Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck. The safety ... This is a Phase II trial to characterize the feasibility of treating patients with locally advanced cutaneous squamous cell ... Phase II Trial of Post-operative or Definitive Concurrent Radiation and Cetuximab for Locally Advanced Cutaneous Squamous Cell ...
Research Administration * TEACHING * Clinical Epidemiology and Population Health Curriculum * Fellowships and Awards * ... Genetically Predicted Serum Vitamin C Levels and Cutaneous Squamous Cell Carcinoma Risk. View Abstract ... Genetically Predicted Serum Vitamin C Levels and Cutaneous Squamous Cell Carcinoma Risk. ...
Primary Cutaneous Follicle-center Lymphoma(PCFCL) is a non-Hodgkins lymphoma subtype. ... Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration ... Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Treating Primary Cutaneous Follicle-center Lymphoma. Patients with ... Prognosis in Primary Cutaneous Follicle-center Lymphoma. In general, the prognosis for most patients with this disease is ...
U.S. Food and Drug Administration. Accessed Oct. 19, 2015. ... Cutaneous and Ocular Toxicology. 2015;Early Online:1. ...
Cutaneous small vessel vasculitis/leukocytoclastic vasculitis. Cutaneous small vessel vasculitis usually presents as palpable ... Note any reaction on re-administration of the drug.. When a drug reaction is suspected, the presence of blisters would almost ... Wolf R, Orion E, Marcos B, Matz H. Life-threatening acute adverse cutaneous drug reactions. Clinics in Dermatology 2005; 23: ... Small vessel cutaneous vasculitis, Drug-induced bullous pemphigoid, Drug-induced and drug-triggered pemphigus, Drug-induced ...
Transient alterations of cutaneous sensory nerve function by non-invasive cryolipolysis  Garibyan, Lilit; Cornelissen, Laura; ... Under a Food and Drug Administration-approved phase 1 Investigational New Drug trial, ... ... for Cutaneous Anesthesia  Lobo, Kimberly; Donado, Carolina; Cornelissen, Laura Louise; Kim, Joseph; Ortiz, Rebeca; Peake, Roy ...
at Department of Health and Human Services Food and Drug Administration in United States 0 0 Department of Health and Human ... Cutaneous pharamcokinetic-based approaches to establish bioequivalence of topically applied drug products ...
As described in this case, the patients purpura, skin lesions, and ulcers improved dramatically after oral administration of ... Allergic cutaneous vasculitis (ACV), also known as cutaneous small vessel vasculitis, allergic small arteritis, or ... reported the overall annual incidence of cutaneous vasculitis as 38.6/million, and that of cutaneous leukocytoclastic angiitis ... Cutaneous vasculitis in a defined population--clinical and epidemiological associations. J Rheumatol. 1998;25:920-924. [PubMed] ...
  • Extracorporeal photopheresis is a non-invasive therapy used for the treatment of a range of T cell disorders, including cutaneous T cell lymphoma. (
  • Primary Cutaneous Follicle-center Lymphoma(PCFCL) is a non-Hodgkin's lymphoma subtype. (
  • Specifically, it is a cutaneous lymphoma, meaning that lesions develop on the skin. (
  • As such, PCFCL is the most commonly diagnosed cutaneous B-cell lymphoma , representing more than half of all cases. (
  • December 2021 - The Cutaneous Lymphoma Foundation is an active member of the Haystack Project , an umbrella nonprofit organization dedicated to supporting rare disease patient organizations in collaborating with stakeholders to find practical and impactful legislative solutions for rare disease patients. (
  • The bill reduces the initial and often extremely high hurdle for rare disease patients (like cutaneous lymphoma) to meet the medical necessity threshold for access and insurance coverage for off-label use of treatments. (
  • Thank you for visiting the Cutaneous Lymphoma Foundation's website. (
  • How is cutaneous T-cell lymphoma (CTCL) diagnosed? (
  • It can take time to diagnose cutaneous T-cell lymphoma (CTCL). (
  • How is cutaneous T-cell lymphoma (CTCL) treated? (
  • The FDA has approved a new immunotherapeutic for treating two types of cutaneous T-cell lymphoma, mycosis fungoides and Sézary syndrome. (
  • The U.S. Food and Drug Administration (FDA) recently approved a new immunotherapeutic called mogamulizumab-kpkc (Poteligeo) for treating certain patients with two rare types of non-Hodgkin lymphoma , mycosis fungoides and Sézary syndrome. (
  • Primary cutaneous B-cell lymphoma in a 74-year-old Caucasian male. (
  • Primary cutaneous B-cell lymphoma is an uncommon neoplasm with classification schemes that may be confusing, but with clinical presentations that are relatively consistent. (
  • Guidelines have been published by the American Academy of Dermatology (last in 2019) regarding biopsy, pathology reporting, and management of primary cutaneous melanoma. (
  • Evidence strongly indicates that Breslow thickness, ulceration, and dermal mitotic rate are important predictors of patient outcome in primary cutaneous melanoma. (
  • Surgical margins for invasive cutaneous melanoma, as measured clinically around the primary tumor, should be a minimum of 1 cm and a maximum of 2 cm, although narrower margins can be used to accommodate function and/or anatomic location. (
  • It is not recommended that asymptomatic patients with newly diagnosed stage 0-II primary cutaneous melanoma undergo baseline radiologic imaging and laboratory studies. (
  • For cutaneous melanoma at baseline, radiologic imaging and laboratory studies should be conducted only to assess the specific signs or symptoms of synchronous metastasis (regional nodal or distant). (
  • Regular clinical follow-up represents the most important strategy for detecting cutaneous melanoma recurrence. (
  • Patients should be taught self-examination of the skin and lymph nodes in order to detect recurrent disease or new primary cutaneous melanoma. (
  • Guidelines on cutaneous melanoma management and systemic therapy for metastatic or unresectable cutaneous melanoma and recommendations for adjuvant systemic therapies were revised in December 2021 (v1.2022) by the National Comprehensive Cancer Network (NCCN). (
  • New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986-2016. (
  • Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. (
  • Frequencies of BRAF and NRAS mutations are different in histologic types and sites of origin of cutaneous melanoma: a meta-analysis. (
  • Early recognition of cutaneous melanoma. (
  • Risk factors for cutaneous melanoma. (
  • Influence of estrogen administration on tumor characteristics and survival in women with cutaneous melanoma. (
  • Exposure to the sun and sunbeds and the risk of knowledge relating to exposure and health cutaneous melanoma in the UK: a case-control risks], Report, Maisons-Alfort, France (in study. (
  • Cutaneous malignant melanoma and exposure by immediate pigmentation induced by 382 nm to sunlamps and sunbeds: a descriptive study in radiation. (
  • Cutaneous malignant melanoma and exposure damage. (
  • Expert Consensus on the Use of Prognostic Gene Expression Profiling Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group. (
  • This is a Phase II trial to characterize the feasibility of treating patients with locally advanced cutaneous squamous cell carcinomas of the head and neck with post-operative radiotherapy and cetuximab. (
  • Regeneron conducted the first pivotal trial of Libtayo in advanced cutaneous squamous cell carcinoma that was unlikely to be curable by surgery or radiation, and we are now studying the utility of Libtayo in earlier stages of this disease. (
  • In the U.S. and other countries Libtayo is indicated in certain patients with advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC) and advanced non-small cell lung cancer (NSCLC), as well as in advanced cervical cancer in Canada and Brazil. (
  • Cemiplimab-rwlc (Libtayo), a PD-1 inhibitor, has transformed the treatment of advanced -cutaneous squamous-cell carcinoma (CSCC), significantly extending survival for patients. (
  • Cutaneous leishmaniasis lesions. (
  • Sixty-six patients with cutaneous leishmaniasis lesions completed the study. (
  • Cutaneous leishmaniasis causes skin lesions with various clinical features from slow-healing lesions to permanent scars (3), resulting in social stigma and psychological disorders that negatively affect the quality of life (4). (
  • Skin plasmacytomas not associated with underlying lesions, also known as secondary cutaneous plasmacytomas (SCP), are rare with less than 100 reported cases [ 1 - 17 ]. (
  • Most people who got sick described having skin lesions, known as cutaneous anthrax. (
  • Oral lesions may develop well before cutaneous manifestations develop. (
  • Although the exact incidence of cutaneous fibrosis is yet to be determined, the prevalence of related disorders, such as scleroderma and keloids, is widely known across the world. (
  • The incidence of cutaneous adverse events (AEs) in cancer patients receiving PI3K inhibitors may be as high as 29%, according to a meta-analysis published in JAMA Oncology . (
  • The meta-analysis included data from phase 2 and phase 3 randomized controlled trials reporting on the efficacy of PI3K inhibitors and the incidence of cutaneous AEs. (
  • Incidence of cutaneous adverse events with phosphoinositide 3-kinase inhibitors as adjuvant therapy in patients with cancer. (
  • Cutaneous manifestations of systemic disease may be the initial complaint that causes patients to seek out a healthcare provider. (
  • Overall mortality rates have been reported to be 48% and 20% for patients with and without cutaneous manifestations, respectively. (
  • Four of these NTDs have cutaneous clinical manifestations. (
  • 5] Cutaneous manifestations of Crohn disease may also be noncontiguous: metastatic Crohn disease is defined as a granulomatous inflammation of the skin that is not contiguous with the GI tract. (
  • Our project investigated the four clinical phenotypes of PCOS based on cutaneous manifestations to establish clinical guidelines to be written in a peer reviewed journal. (
  • Topical delivery is preferable over systemic delivery for cutaneous leishmaniasis (CL), because of its easy administration, reduced systemic adverse effects, and low cost. (
  • High prevalence and incidence rate of systemic scleroderma disease over the world, is driving cutaneous fibrosis treatment market growth. (
  • The treatment of Pemphigus vulgaris involves the administration of oral and systemic corticosteroids in the early stages to control the disease, which, if handled improperly, can be fatal. (
  • Neglected tropical diseases (NTDs) such as cutaneous leishmaniasis (CL) are often associated with rural territories and vulnerable communities with limited access to health care services. (
  • Cutaneous leishmaniasis is a vector-borne parasitic disease caused by different Leishmania species and transmitted through sand fly bites, specifically in uncovered parts of the body. (
  • Three species of cutaneous Leishmania are seen in the Americas. (
  • The present case reminds U.S. clinicians that leishmaniasis should be included in the differential diagnosis of cutaneous ulcers in travelers, foreign visitors, and immigrants from endemic areas. (
  • Approximately 15 years after original diagnosis, he developed secondary cutaneous plasmacytomas of the right arm, right chest wall, and right upper back over the course of several months. (
  • Due to a lack of understanding among healthcare professionals and the general public, cutaneous fibrosis diagnosis and treatment are usually delayed. (
  • PARIS AND TARRYTOWN, NY - September 28, 2018 - The U.S. Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. (
  • Three died while receiving treatment while two were lost on follow-up.Conclusion: Death arising from metastatic cutaneous breast cancer is a good index for surgical audit. (
  • Occupational exposure involving potentially contaminated biological material (PCBM) are characterized as percutaneous (injuries due to sharps), muco-cutaneous (exposure of ocular, nasal, oral and genital mucosa and non-intact skin) accidents and human bites(3). (
  • Consider interrupting breastfeeding and pumping and discarding breast milk up to18 hours after Gadavist administration in order to minimize exposure to a breastfed infant. (
  • Induction exposure is the administration of a test substance to the test subject with the intention of inducing contact sensitization. (
  • Imaging mass spectrometry for assessing cutaneous wound healing: analysis of pressure ulcers. (
  • IMSEAR at SEARO: Dextranomer dressing in the treatment of infected wounds and cutaneous ulcers. (
  • Drug delivery to local subcutaneous structures following topical administration. (
  • This article brings together a collection of results and observations which demonstrate the achievement of significant drug delivery to local subcutaneous structures following topical administration. (
  • On closer perusal of the literature, however, it becomes apparent that a small but significant number of reports exist which show that deeper penetration can take place and that subcutaneous drug levels can be achieved following topical application which cannot be reached after parenteral or oral administration of the active agent. (
  • TARRYTOWN, N.Y., Sept. 12, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive clinical data for an investigational regimen of PD-1 inhibitor Libtayo ® (cemiplimab) as neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma (CSCC). (
  • The following case history describes a cutaneous infection suspected to be anthrax in a tourist who had indirect contact with dead mammals in a disease-endemic area. (
  • The clinical aspect and history strongly suggested cutaneous anthrax. (
  • Initial skin lesion with black crust and red border, suggestive of cutaneous anthrax. (
  • Because cutaneous anthrax was suspected, wound crusts, swabs for bacterial cultures, and Dacron swabs used for PCR were mailed as quickly as possible to the Belgian national reference laboratory. (
  • Information about this suspected case of cutaneous anthrax was also sent to the veterinary officers. (
  • Rising cutaneous fibrosis-related disorders are likely to fuel the growth of the cutaneous fibrosis treatment market. (
  • The following aspects of specific occupational diseases were covered in the plans for this fiscal year: behavioral and neurotoxic effects, cancer, reproductive effects, respiratory disease, musculoskeletal and connective tissue disorders, cutaneous disease, sensory disorders, cardiovascular disease, and infective and parasitic disorders. (
  • We attempt to enhance the understanding of cutaneous pathophysiology and improve the clinician's ability to diagnose and treat skin disorders. (
  • Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. (
  • The global cutaneous fibrosis treatment market was valued at US$ 574.6 Mn in 2021, with a projected CAGR of 6.8% for the next ten years, which indicates highly positive market growth. (
  • According to Persistence Market Research, cutaneous fibrosis treatment solutions enjoyed a valuation of US$ 574.6 Mn in 2021 and accounted for 12.6% share of the global fibrotic disease treatment market. (
  • The global market for cutaneous fibrosis treatment expanded at a CAGR of 5.1% over the last five years (2017-2021). (
  • In the neoadjuvant trial in stage II to IV cutaneous squamous cell carcinoma presented at ESMO and published in NEJM , Libtayo demonstrated greater than 60% response rates per both pathologic and imaging measures. (
  • Libtayo may therefore have expanded utility in earlier stages of cutaneous squamous cell carcinoma as a monotherapy to potentially help avoid surgery, and as part of a combination approach with surgery to facilitate function-preserving resections and minimize disfigurement. (
  • Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. (
  • 2018 . Synergy between conventional antibiotics and antibiofilm peptides in a murine, sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens. (
  • 2) health service barriers, with factors related to administration, insufficient health infrastructure and coverage, and (3) CL treatment, which covers perceptions of the treatment and issues related to the implementation of national CL treatment guidelines. (
  • It was approved by the United States Food and Drug Administration (FDA) in 2006 for the treatment of head and neck cancer. (
  • The purpose of this study is to determine how easily cetuximab can be added to treatment with radiation therapy in patients with cutaneous cancer of the head and neck. (
  • Detailed industry analysis reveals that revenue from cutaneous fibrosis treatment will surge to a market valuation of US$ 1.2 Bn by the end of 2032. (
  • In the previous decade, numerous research activities on cutaneous fibrosis treatment have been conducted to examine the treatment choices and disease epidemiology, with the goal of better understanding the disease prognosis. (
  • There is currently no approved treatment for cutaneous fibrosis. (
  • Novel therapeutics for the treatment of cutaneous fibrosis conditions are being developed by several researchers and sponsors. (
  • Anti-retroviral treatment has contained HIV spread in the Western world, but it is not curative and its high cost prohibits worldwide administration. (
  • The treatment included aggressive intravenous fluid resuscitation, administration of dopamine, and antimicrobial agent therapy with teicoplamin and clindamycin. (
  • It is used for the treatment of breast cancer and cutaneous metastasis. (
  • Therefore, the purpose of this contemporary investigation is to determine whether lidocaine administration has any analgesic effect on reducing maternal pain during amniocentesis when contrasted with a control treatment. (
  • The hypothesis is that the lidocaine administration will correlate with better maternal analgesia than the control treatment during amniocentesis. (
  • Two drugs are approved by the Food and Drug Administration in the United States for treatment of psoriatic arthritis-secukinumab and ixekizumab. (
  • To evaluate safety and efficacy of Lip-AmB 0.4% in cutaneous leishmaniasis patients. (
  • The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with. (
  • Cutaneous AEs of any grade were reported in 29.30% of patients treated with PI3K inhibitors and 13.0% of patients in the control population. (
  • There were 15 studies with data on cutaneous AEs of any grade, and the studies encompassed a total of 4200 patients. (
  • There were 14 studies that included data on grade 3 or higher cutaneous AEs, and these studies included a total of 3750 patients. (
  • Instruct patients on proper administration of insulin, check insulin label before each injection, and management of hypoglycemia. (
  • Cutaneous involvement consists of similar ulcerations that may arise on the buttocks, abdomen, thighs, and face, although in rare cases patients may develop pyoderma vegetans. (
  • The second study achieved this through the administration of acetylcholine, which triggered an increased axon reflex response among type 2 rosacea patients. (
  • On the basis of anatomical location and clinical stage, there are six clinical forms of mucormycosis: naso-orbital-cerebral, pulmonary, cutaneous, disseminated, gastrointestinal and rarer forms. (
  • Shaved mouse with cutaneous leishmaniasis with lesion at base of the tail. (
  • In 2004, I was diagnosed with Antiphospholipid Antibody Syndrome, Connective Tissue Disorder and Cutaneous Lupus. (
  • Editorial Note: An estimated 12 million cases of leishmaniasis, visceral and cutaneous, occur worldwide each year (1). (
  • Since no medicine has been approved to treat cutaneous fibrosis, drug manufacturing companies are evaluating the efficacy and activity of a variety of treatments. (
  • Cutaneous involvement from these tumors is usually in the setting of direct extension from underlying plasmacytomas. (
  • Following intravenous administration, MEGX and GX concentrations in serum range from 11 to 36% and from 5 to 11% of lidocaine concentrations, respectively. (
  • Intravenous infusion administration: a comparative study of practices and errors between the United States and England and their implications for patient safety. (
  • 59 (70.2) had had some experience with intravenous antibiotics administration. (
  • The ulcer became larger despite administration of oral erythromycin and dicloxacillin. (
  • Cutaneous Renal and Glomerular Vasculopathy (CRGV) or Alabama Rot in dogs, is typically characterized by ulceration or erosions of the distal limbs, ventrum or oral cavity/muzzle and it is variably associated with acute kidney injury (AKI). (
  • The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral. (
  • Objective -To evaluate the effect of oral administration of dexamethasone (DEX) at clinically relevant doses on metabolic activities of cytochrome P450 (CYP) isoenzymes in dogs and rats. (
  • Interestingly, cutaneous endothelial responses remained similar between subjects and controls, suggesting that neural pathways rather than cutaneous vascular function are responsible for regulating blushing. (
  • Skin sensitization (allergic contact dermatitis) is an immunologically mediated cutaneous reaction to a substance. (
  • Contact dermatitis is an adverse cutaneous reaction resulting from direct contact with irritant or allergic substances. (
  • In keeping with the objective of identifying drugs for prolonged cutaneous analgesia, the authors compared the cutaneous analgesic effectiveness of amitriptyline and bupivacaine in rats. (
  • Complete recovery from the cutaneous analgesia elicited by 0.05% and 0.5 amitriptyline versus 0.05 and 0.5% bupivacaine occurred in 9.9 +/- 0.2 and 19.3 +/- 0.4 h versus 2.2 +/- 0.1 and 16.1 +/- 0.2 h, respectively (mean +/- SE). (
  • The researchers also conducted a subgroup analysis looking at cutaneous AEs by PI3K inhibitor class. (
  • Amitriptyline is a longer-acting local anesthetic compared with bupivacaine for cutaneous infiltration. (
  • Cutaneous leishmaniasis (CL) is the most common clinical presentation of leishmaniases, a group of parasitic diseases transmitted by sandflies, and is a Neglected Tropical Disease of the skin (skin NTD). (
  • Connective tissue fibrosis typically occurs in indications such as keloids, scleroderma , radiation-induced skin fibrosis, and chronic graft-versus-host disease-associated (GVHD) cutaneous fibrosis. (
  • An intended site for a dose form that is for administration by application to the skin, cutaneous wounds, nails or hair. (
  • These Food and Drug Administration (FDA) -approved ingredients can be some of the most effective ways to protect oneself from harmful UVA and UVB rays, which is key to preventing sunburn and potential skin cancer. (
  • SKIN: Journal of Cutaneous Medicine. (
  • In January 2006, the United States Food and Drug Administration (FDA) announced that Elidel packaging would be required to carry a black box warning regarding the potential increased risk of lymph node or skin cancer , as for the similar drug tacrolimus . (
  • The cutaneous operative wound was red and swollen. (
  • Note any reaction on re-administration of the drug. (
  • Increased risk of hyperglycemia or hypoglycemia if changes in physical activity, meal patterns, concomitant medications, renal or hepatic function, insulin regimen, administration site, and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. (
  • A low or absent titer for cutaneous leishmaniasis does not rule out infection, as antibody may not be produced. (
  • Cutaneous leishmaniasis is the most common form of leishmaniasis and it is endemic in about 90 countries, with 600 000 to 1 million new cases annually. (
  • In addition to the drug acquisition and administration costs, the researchers evaluated costs associated with adverse events, subsequent therapy, disease management, and terminal care. (
  • Non-Hodgkin lymphomas with these disease characteristics are grouped together and called cutaneous cutaneous T-cell lymphomas . (
  • This journal has a particular interest in publishing clinical and laboratory studies that reveal new information pertinent to the interests and needs of the medical dermatologist, dermatologic surgeon, and all those concerned with state-of-the-art care of cutaneous disease. (
  • Daily online exclusives cover late breaking oncology news, safe handling and administration of chemotherapy drugs, side effect management, and new developments in specific cancers. (
  • Inaccurate and unreliable medical tests are prompting abortions, promoting unnecessary surgeries, putting tens of thousands of people on unneeded drugs and raising medical costs, the Food and Drug Administration has concluded. (
  • Furthermore, they conducted 4 phase I clinical trials to test the prophylactic and therapeutic capacity of DNA and MVA-HIV vaccine applied by various routes including transcutaneous needle-free administration. (
  • Subgroup analysis was performed according to the mode of administration. (
  • Subgroup analysis according to the mode of administration showed that pain perception did not significantly differ between both arms when lidocaine was employed as injection [n=3 RCTs, MD=-0.26, 95% CI (-0.76, 0.23), p=0.29] or non-injection [n=2 RCTs, MD=-0.18, 95% CI (-0.55, 0.18), p=0.33]. (
  • The US Food and Drug Administration (FDA) has approved Cabenuva , an injectable formulation of cabotegravir (Vocabria) and rilpivirine (Edurant), for adults living with HIV-1 infection. (
  • Cutaneous Procedures Adverse Events Reporting (CAPER). (
  • This guidance document describes a means by which cutaneous carbon dioxide (PcCO 2 ) and oxygen (PcO 2 ) monitor devices may comply with the requirement of special controls for class II devices. (
  • The Food and Drug Administration (FDA) believes that the recommendations in this guidance document will improve the quality of postmarketing safety reports and clarify the industry's current safety reporting responsibility to assure public health. (